CA2344453A1 - Analytical test device and method of use - Google Patents
Analytical test device and method of use Download PDFInfo
- Publication number
- CA2344453A1 CA2344453A1 CA002344453A CA2344453A CA2344453A1 CA 2344453 A1 CA2344453 A1 CA 2344453A1 CA 002344453 A CA002344453 A CA 002344453A CA 2344453 A CA2344453 A CA 2344453A CA 2344453 A1 CA2344453 A1 CA 2344453A1
- Authority
- CA
- Canada
- Prior art keywords
- absorbent
- membrane
- sample
- test device
- analytical test
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Abandoned
Links
Classifications
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
- G01N33/558—Immunoassay; Biospecific binding assay; Materials therefor using diffusion or migration of antigen or antibody
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
- G01N33/543—Immunoassay; Biospecific binding assay; Materials therefor with an insoluble carrier for immobilising immunochemicals
- G01N33/54366—Apparatus specially adapted for solid-phase testing
-
- Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
- Y10—TECHNICAL SUBJECTS COVERED BY FORMER USPC
- Y10S—TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
- Y10S435/00—Chemistry: molecular biology and microbiology
- Y10S435/97—Test strip or test slide
-
- Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
- Y10—TECHNICAL SUBJECTS COVERED BY FORMER USPC
- Y10S—TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
- Y10S436/00—Chemistry: analytical and immunological testing
- Y10S436/807—Apparatus included in process claim, e.g. physical support structures
Abstract
The present invention provides an analytical test device for conducting assays of biological fluids. Methods for carrying out the assays with the disclosed analytical test device are also provided.
Description
ANALYTICAL TEST DEVICE AND METHOD OF USE
FIELD OF THE INVENTIQN
This invention relates to a novel analytical test device for analysis of biological fluids such as urine.
The invention furi~her relates to methods for detecting analytes in fluids using the test device.
fiACRGROUND INFORMATION
The sampling and testing of biological fluids such as urine for the presence of analytes provide important information regarding various health-related matters, including pregnancy and conception.
In recent years, test devices have undergone nearly continuous refinement in an effort to simplify and speed the process of detecting selected ligand in fluids. As a result of this work, current test devices use an immunoassay for determining pregnancy or conception. In these devices a reagent, such as an antibody, specifically reacts with an analyte to form a complex, which can usually be detected by the unaided eye.
Current pregnancy test devices assay for hormones associated with pregnancy, such as, for example, chorionic gonadotrophin (hereinafter "hCG") since the presence of hCG
in urine is usually an indicator that a woman is pregnant.
Such test devices obtain qualitative results indicating either the presence or absence of hCG. Typically, a pregnancy immunoas~>ay contains an antibody directed against hCG. The reaction complex can then be viewed by th.e user.
Conception test devices also assay for hormones associated with the ovarian cycle, such as, for example, luteinizing hormone (hereinafter "LH"). LH is present
FIELD OF THE INVENTIQN
This invention relates to a novel analytical test device for analysis of biological fluids such as urine.
The invention furi~her relates to methods for detecting analytes in fluids using the test device.
fiACRGROUND INFORMATION
The sampling and testing of biological fluids such as urine for the presence of analytes provide important information regarding various health-related matters, including pregnancy and conception.
In recent years, test devices have undergone nearly continuous refinement in an effort to simplify and speed the process of detecting selected ligand in fluids. As a result of this work, current test devices use an immunoassay for determining pregnancy or conception. In these devices a reagent, such as an antibody, specifically reacts with an analyte to form a complex, which can usually be detected by the unaided eye.
Current pregnancy test devices assay for hormones associated with pregnancy, such as, for example, chorionic gonadotrophin (hereinafter "hCG") since the presence of hCG
in urine is usually an indicator that a woman is pregnant.
Such test devices obtain qualitative results indicating either the presence or absence of hCG. Typically, a pregnancy immunoas~>ay contains an antibody directed against hCG. The reaction complex can then be viewed by th.e user.
Conception test devices also assay for hormones associated with the ovarian cycle, such as, for example, luteinizing hormone (hereinafter "LH"). LH is present
2 normally in urine but its concentration increases markedly during ovulation, l:he time at which a woman is most likely to conceive. Thus, the probability that a woman can conceive a child varies directly with LH concent:ration.
Such test devices obtain semi-quantitative results regarding the relative concentration of LH in the urine.
Typically, a conception immunoassay contains an antibody directed against L:H and a separate detection antibody.
In known devices, the fluid to be tested wicks up through an absorbent: membrane that is in fluid flow contact with the reagents that detect an analyte in a fluid. A
major problem with this type of device is that as the fluid progresses through the membrane, the front edge of the fluid is uneven. The uneven fluid front will cause the results to be smeared, produce false negatives and make the results difficult to detect. These artifacts are called "leading edge effects." An uneven fluid front can arise for a variety of reasons, for example, because the sample is not uniformly applied to the absorbent membrane.
Therefore, a need exists for a device that does not produce an uneven fluid front and associated leading edge effects. The present invention provides a device that eliminates the uneven fluid front problem and related methads of using such a device.
SUMMARY OF THE INVENTION
The present invention provides an analytical test device for analyzing biological fluids, for example, urine.
The device has a t.op with one or more display ports and, optionally, a receiving port and a vertical bar. The device also has a bottom and, optionally, a receiving port, an upper plane, a slope and a lower plane. The device
Such test devices obtain semi-quantitative results regarding the relative concentration of LH in the urine.
Typically, a conception immunoassay contains an antibody directed against L:H and a separate detection antibody.
In known devices, the fluid to be tested wicks up through an absorbent: membrane that is in fluid flow contact with the reagents that detect an analyte in a fluid. A
major problem with this type of device is that as the fluid progresses through the membrane, the front edge of the fluid is uneven. The uneven fluid front will cause the results to be smeared, produce false negatives and make the results difficult to detect. These artifacts are called "leading edge effects." An uneven fluid front can arise for a variety of reasons, for example, because the sample is not uniformly applied to the absorbent membrane.
Therefore, a need exists for a device that does not produce an uneven fluid front and associated leading edge effects. The present invention provides a device that eliminates the uneven fluid front problem and related methads of using such a device.
SUMMARY OF THE INVENTION
The present invention provides an analytical test device for analyzing biological fluids, for example, urine.
The device has a t.op with one or more display ports and, optionally, a receiving port and a vertical bar. The device also has a bottom and, optionally, a receiving port, an upper plane, a slope and a lower plane. The device
3 further has a strip made up of an absorbent membrane, a reaction membrane with one or more reagents that form a reaction complex with an analyte in a fluid sample and, optionally, a collecting pad. The device also has an absorbent sample pad in a container and a stopping means.
The absorbent membrane, the reaction membrane and the collecting pad, when present, are in fluid flow contact with one another. The strip is placed on the bottom such that the reaction membrane is visible through the display port and the absorbent membrane is toward the receiving port. The top or the bottom has the receiving port or together the top and the bottom form the receiving port and in the assembled top and bottom the absorbent sample pad is slidably insertab~Le through the receiving port until stopped by the stopping means, which places the absorbent sample pad in f.l.uid flow contact with the absorbent membrane.
In one embodiment, the analytical test device also has the top with t:he optional vertical bar. The vertical bar deflects the absorbent membrane to follow the contour of the slope. The bottom has the optional lower plane, upper plane and slope and also a stopping means.
The present invention also provides methods for detecting an analyte in a fluid sample, comprising adding fluid sample to the absorbent sample pad, inserting the absorbent sample pad into the receiving port until the absorbent sample pad is stopped by the stopping means and detecting the anal.yte by observing the reaction complex through the display port. In one method the reaction complex is visible.
The absorbent membrane, the reaction membrane and the collecting pad, when present, are in fluid flow contact with one another. The strip is placed on the bottom such that the reaction membrane is visible through the display port and the absorbent membrane is toward the receiving port. The top or the bottom has the receiving port or together the top and the bottom form the receiving port and in the assembled top and bottom the absorbent sample pad is slidably insertab~Le through the receiving port until stopped by the stopping means, which places the absorbent sample pad in f.l.uid flow contact with the absorbent membrane.
In one embodiment, the analytical test device also has the top with t:he optional vertical bar. The vertical bar deflects the absorbent membrane to follow the contour of the slope. The bottom has the optional lower plane, upper plane and slope and also a stopping means.
The present invention also provides methods for detecting an analyte in a fluid sample, comprising adding fluid sample to the absorbent sample pad, inserting the absorbent sample pad into the receiving port until the absorbent sample pad is stopped by the stopping means and detecting the anal.yte by observing the reaction complex through the display port. In one method the reaction complex is visible.
4 Figure 1 is <3 perspective view of the analytical test device containing an absorbent sample pad in a container.
Figure 2 is an exploded view showing the components of the analytical test device of Figure 1.
Figure 3 is a perspective view of an embodiment of an analytical test device with an absorbent sample pad inside.
a container.
Figure 4 is an exploded view showing the components of the analytical teat device of Figure i.
Figure 5 is an enlarged sectional view along line 5-5 of the analytical test device of Figure 3 showing that the absorbent sample pad is not in fluid flow contact with the absorbent membrane.
Figure 6 is an enlarged sectional view along 5-5 of the analytical test device of Figure 3 showing that the absorbent sample pad is in fluid flow contact with the absorbent membrane.
Figure 7 is a perspective view of an embodiment of an analytical test device containing a slidably insertable absorbent sample pad in a container.
Figure 8 is a.n exploded view showing the components of the analytical test device of Figure 7.
Figure 9 is an enlarged sectional view along line 9-9 of the analytical test device of Figure 7 showing initial placement of the absorbent sample pad not in fluid flow contact with the absorbent membrane.
SUBSTITUTE SHEET (RULE 261 Figure 10 is an enlarged sectional view along line 9-9 of the analytical test device of Figure 7 showing placement of the absorbent sample pad in fluid flow contact with the absorbent membrane.
Figure 2 is an exploded view showing the components of the analytical test device of Figure 1.
Figure 3 is a perspective view of an embodiment of an analytical test device with an absorbent sample pad inside.
a container.
Figure 4 is an exploded view showing the components of the analytical teat device of Figure i.
Figure 5 is an enlarged sectional view along line 5-5 of the analytical test device of Figure 3 showing that the absorbent sample pad is not in fluid flow contact with the absorbent membrane.
Figure 6 is an enlarged sectional view along 5-5 of the analytical test device of Figure 3 showing that the absorbent sample pad is in fluid flow contact with the absorbent membrane.
Figure 7 is a perspective view of an embodiment of an analytical test device containing a slidably insertable absorbent sample pad in a container.
Figure 8 is a.n exploded view showing the components of the analytical test device of Figure 7.
Figure 9 is an enlarged sectional view along line 9-9 of the analytical test device of Figure 7 showing initial placement of the absorbent sample pad not in fluid flow contact with the absorbent membrane.
SUBSTITUTE SHEET (RULE 261 Figure 10 is an enlarged sectional view along line 9-9 of the analytical test device of Figure 7 showing placement of the absorbent sample pad in fluid flow contact with the absorbent membrane.
5 Figure 11 i~; a perspective view of the absorbent and reaction membranes of the analytical test device employing a sandwich assay system showing a positive assay result.
Figure 12 is a perspective view of the absorbent and reaction membranes of the analytical test device employing a sandwich assay system showing a negative assay result.
Figure 13 is a perspective view of the absorbent and reaction membranes of the analytical test device employing a sandwich assay system showing an inconclusive assay result.
Figure 14 is a perspective view of the absorbent and reaction membranes of an embodiment of the analytical test device employing a competitive assay system showing a positive assay result.
Figure 15 is a perspective view of the absorbent and reaction membranes of an embodiment of the analytical test device employing a competitive assay system showing a negative assay result.
DETAILED DESC#tIPTION OF THE INVENTION
The present invention is directed to an analytical test device that eliminates the uneven fluid front and leading edge effects associated with prior devices. The analytical test device ensures that fluid sample comes into fluid flow contact with the membrane that contains the reagents to detect the analyte, evenly and at the same SUBSTITUTE SHEET (RULE 261
Figure 12 is a perspective view of the absorbent and reaction membranes of the analytical test device employing a sandwich assay system showing a negative assay result.
Figure 13 is a perspective view of the absorbent and reaction membranes of the analytical test device employing a sandwich assay system showing an inconclusive assay result.
Figure 14 is a perspective view of the absorbent and reaction membranes of an embodiment of the analytical test device employing a competitive assay system showing a positive assay result.
Figure 15 is a perspective view of the absorbent and reaction membranes of an embodiment of the analytical test device employing a competitive assay system showing a negative assay result.
DETAILED DESC#tIPTION OF THE INVENTION
The present invention is directed to an analytical test device that eliminates the uneven fluid front and leading edge effects associated with prior devices. The analytical test device ensures that fluid sample comes into fluid flow contact with the membrane that contains the reagents to detect the analyte, evenly and at the same SUBSTITUTE SHEET (RULE 261
6 PCTlUS98/27705 height across the membrane, thereby producing an even fluid front.
Fluid sample is collected in an absorbent sample pad that is initially not in fluid flow contact with the absorbent membrane. Then the absorbent sample pad is contacted to the absorbent membrane so that the fluid sample comes into fluid flow contact with the absorbent membrane. The edge of the absorbent sample pad contacts the absorbent membrane orthogonal to the absorbent membrane, ensuring that the fluid sample will contact the absorbent membrane evenly and at the same height across the membrane.
A further advantage of the analytical test device is that the user can control when the assay starts. Thus, if desired, the user ca.n add more than one fluid sample to the absorbent sample pad before the assay starts. This feature is especially important where the user only wishes to know whether an analyte is present in more than one fluid sample. In prior cLevices, once the fluid sample is added, the assay proceeds and the reagents are depleted before a second sample can be added. Thus, the user is not given the time to test additional samples.
The analytical test device of the present invention includes a top and a bottom. The top has a display port that allows the user to see the results. Preferably, the top will have a first display port and a second display port that are in close proximity for easy comparison of results. The bottom has a receiving port for an absorbent sample pad. Inside the device is a strip formed by an absorbent membrane, a reaction membrane and, optionally, a collecting pad. 'fhe absorbent membrane and the reaction membrane contain the reagents to detect an analyte in the fluid sample. When the top is placed on the bottom in the
Fluid sample is collected in an absorbent sample pad that is initially not in fluid flow contact with the absorbent membrane. Then the absorbent sample pad is contacted to the absorbent membrane so that the fluid sample comes into fluid flow contact with the absorbent membrane. The edge of the absorbent sample pad contacts the absorbent membrane orthogonal to the absorbent membrane, ensuring that the fluid sample will contact the absorbent membrane evenly and at the same height across the membrane.
A further advantage of the analytical test device is that the user can control when the assay starts. Thus, if desired, the user ca.n add more than one fluid sample to the absorbent sample pad before the assay starts. This feature is especially important where the user only wishes to know whether an analyte is present in more than one fluid sample. In prior cLevices, once the fluid sample is added, the assay proceeds and the reagents are depleted before a second sample can be added. Thus, the user is not given the time to test additional samples.
The analytical test device of the present invention includes a top and a bottom. The top has a display port that allows the user to see the results. Preferably, the top will have a first display port and a second display port that are in close proximity for easy comparison of results. The bottom has a receiving port for an absorbent sample pad. Inside the device is a strip formed by an absorbent membrane, a reaction membrane and, optionally, a collecting pad. 'fhe absorbent membrane and the reaction membrane contain the reagents to detect an analyte in the fluid sample. When the top is placed on the bottom in the
7 assembled device, t:he absorbent membrane will be positioned on the bottom toward the receiving port and the reaction membrane will be positioned on the bottom underneath the display port.
The absorbent sample pad is held in a container. In one embodiment, they absorbent sample pad will be protruding from the container. Fluid sample is deposited on the absorbent sample pad and, if desired, more than one fluid sample can be applied or contacted with the absorbent sample pad before t:he test is allowed to proceed. At this point the absorbent sample pad is not in fluid flow contact with the strip. The absorbent sample pad is then inserted into the receiving port until the absorbent sample pad is in fluid flow contact with the absorbent membrane. The analytical test d~avice also has a stopping means that prevents the absorbent sample pad from reaching far enough into the assembled t:op and bottom to by-pass the absorbent membrane and contact the reaction membrane.
The bottom of the analytical test device of the present invention can also be divided into an upper plane and a lower plane by a slope . As used herein, the term "slope" refers to a surface or plane of the bottom of the device that is at such an angle in relation to the other planes of the bottom that it slows the rate of fluid sample wicking through the absorbent membrane. Thus, the slope prevents an excess amount of fluid sample migrating through the absorbent membrane, which would otherwise and compromise the assa y.
When the slope is present, the absorbent membrane is along the lower plane and the slope and the reaction membrane is on thF~ upper plane. Also, the analytical test device has a vertical bar extending downward from the top.
As used herein, the term "vertical bar" refers to a part of
The absorbent sample pad is held in a container. In one embodiment, they absorbent sample pad will be protruding from the container. Fluid sample is deposited on the absorbent sample pad and, if desired, more than one fluid sample can be applied or contacted with the absorbent sample pad before t:he test is allowed to proceed. At this point the absorbent sample pad is not in fluid flow contact with the strip. The absorbent sample pad is then inserted into the receiving port until the absorbent sample pad is in fluid flow contact with the absorbent membrane. The analytical test d~avice also has a stopping means that prevents the absorbent sample pad from reaching far enough into the assembled t:op and bottom to by-pass the absorbent membrane and contact the reaction membrane.
The bottom of the analytical test device of the present invention can also be divided into an upper plane and a lower plane by a slope . As used herein, the term "slope" refers to a surface or plane of the bottom of the device that is at such an angle in relation to the other planes of the bottom that it slows the rate of fluid sample wicking through the absorbent membrane. Thus, the slope prevents an excess amount of fluid sample migrating through the absorbent membrane, which would otherwise and compromise the assa y.
When the slope is present, the absorbent membrane is along the lower plane and the slope and the reaction membrane is on thF~ upper plane. Also, the analytical test device has a vertical bar extending downward from the top.
As used herein, the term "vertical bar" refers to a part of
8 the top of the device extending downward from the top at a point just in front of the slope that holds or deflects the absorbent membrane to follow the contour of the slope.
Optionally, the vertical bar can extend downward far enough to only allow fluid sample to proceed further into the device by wicking through the absorbent membrane.
In one embodiment, the absorbent sample pad is inside a container that c:an be slidably inserted through the receiving port until it comes into fluid flow contact with the absorbent membrane. In a further embodiment, the absorbent sample p;sd is in a container separate from the assembled top and bottom. The absorbent sample pad protrudes from the container and can be inserted into the receiving port. In another embodiment, the absorbent sample pad is in a container that is disposed between the assembled top and bottom of the analytical test device, and partially protruding therefrom. A knob attached to the container allows the user to slide the container inside the device until the stopping means stops the container and the absorbent sample pad contacts the absorbent membrane.
An amount of fluid sample, such as urine, which is suspected of containing, for example hCG, is applied by dropping or pouring (from a pipette or other container) the sample onto the absorbent sample pad. Alternatively, in one embodiment, the absorbent sample pad can be dipped into a fluid sample. I:n addition, the absorbent sample pad may be wetted by carefully holding in a stream of urine. The absorbent sample pad is then contacted with the absorbent membrane by inserting the absorbent sample pad through the receiving port until the container is stopped by the stopping means.
The fluid sample then proceeds by capillary action (i.e., wicki.ng) thi:ough the absorbent membrane. Bound
Optionally, the vertical bar can extend downward far enough to only allow fluid sample to proceed further into the device by wicking through the absorbent membrane.
In one embodiment, the absorbent sample pad is inside a container that c:an be slidably inserted through the receiving port until it comes into fluid flow contact with the absorbent membrane. In a further embodiment, the absorbent sample p;sd is in a container separate from the assembled top and bottom. The absorbent sample pad protrudes from the container and can be inserted into the receiving port. In another embodiment, the absorbent sample pad is in a container that is disposed between the assembled top and bottom of the analytical test device, and partially protruding therefrom. A knob attached to the container allows the user to slide the container inside the device until the stopping means stops the container and the absorbent sample pad contacts the absorbent membrane.
An amount of fluid sample, such as urine, which is suspected of containing, for example hCG, is applied by dropping or pouring (from a pipette or other container) the sample onto the absorbent sample pad. Alternatively, in one embodiment, the absorbent sample pad can be dipped into a fluid sample. I:n addition, the absorbent sample pad may be wetted by carefully holding in a stream of urine. The absorbent sample pad is then contacted with the absorbent membrane by inserting the absorbent sample pad through the receiving port until the container is stopped by the stopping means.
The fluid sample then proceeds by capillary action (i.e., wicki.ng) thi:ough the absorbent membrane. Bound
9 evenly and at the same height extending from side to side of the absorbent membrane, at a downstream point spatially separated from the point where the absorbent sample pad contacts the absorbent membrane and downstream from the vertical bar is a diffusively bound labeled reagent. The spatial separation Erasures that the fluid sample wicks up through the absorbent membrane to contact the diffusively bound labeled reagent. Thus, the diffusively bound .labeled reagent stays within the absorbent membrane and does not migrate into the :fluid sample, which would otherwise destroy the performance of the assay.
If analyte is present in the fluid sample it will complex with the di.ffusively bound labeled reagent. Fluid sample containing either diffusively bound labeled reagent alone or a diffusively bound labeled reagent/analyte complex (i.e., "fir;st complex") will move by wicking up to a "test region" in i:he reaction membrane. Bound evenly and at the same height. extending from side to side of the reaction membrane in the test region is a non-diffusively bound reagent capable of complexing the first complex. The non-diffusively bound reagent may be non-diffusively bound to the membrane by means known in the art, including covalent bonding or attachment to an insoluble protein-coated surface (see, for example, U.S. Patent No.
4,200,690, which i.s incorporated herein by refer_ence).
Preferably, the non--diffusively bound reagent will be bound in a bar shape extending from side to side of the reaction membrane in a manner similar to the attachment of the diffusively bound labeled reagent to the absorbent membrane.
if a first complex is present in the fluid sample, the analyte portion of the first complex will bind to the non-diffusively bound reagent creating a detectable signal, preferably a visible straight line or bar. extending from side to side of the reaction membrane at the first display port. As a cont:r_ol, fluid sample will continue its migration past the first display port to a "control region"
portion of the reacaion membrane.
5 The control region is so called because bound evenly and at the same height extending from side to side of the reaction membrane is a non-diffusively bound control reagent. The diffU.sively bound labeled reagent, complexed with analyte or not, will bind to the non-diffusively bound
If analyte is present in the fluid sample it will complex with the di.ffusively bound labeled reagent. Fluid sample containing either diffusively bound labeled reagent alone or a diffusively bound labeled reagent/analyte complex (i.e., "fir;st complex") will move by wicking up to a "test region" in i:he reaction membrane. Bound evenly and at the same height. extending from side to side of the reaction membrane in the test region is a non-diffusively bound reagent capable of complexing the first complex. The non-diffusively bound reagent may be non-diffusively bound to the membrane by means known in the art, including covalent bonding or attachment to an insoluble protein-coated surface (see, for example, U.S. Patent No.
4,200,690, which i.s incorporated herein by refer_ence).
Preferably, the non--diffusively bound reagent will be bound in a bar shape extending from side to side of the reaction membrane in a manner similar to the attachment of the diffusively bound labeled reagent to the absorbent membrane.
if a first complex is present in the fluid sample, the analyte portion of the first complex will bind to the non-diffusively bound reagent creating a detectable signal, preferably a visible straight line or bar. extending from side to side of the reaction membrane at the first display port. As a cont:r_ol, fluid sample will continue its migration past the first display port to a "control region"
portion of the reacaion membrane.
5 The control region is so called because bound evenly and at the same height extending from side to side of the reaction membrane is a non-diffusively bound control reagent. The diffU.sively bound labeled reagent, complexed with analyte or not, will bind to the non-diffusively bound
10 control reagent present in the control region. This binding will create a detectable signal, preferably a visible straight line or bar extending from side to side of the reaction membrane at the second display port. For ease of comparison, the shape and orientation of the non-diffusively bound control reagent should be similar to the shape and orientation of the non-diffusively bound reagent. In addition, the non-diffusively bound control reagent may be non-~diffusively bound in the manner similar to that of the non-diffusively bound reagent, described above. When the top is aligned with the bottom in the assembled device th,e diffusively bound labeled reagent will be bound so as to be spatially separated from the point where the absorbent sample pad contacts the absorbent membrane, the non-diffusively bound reagent will be bound beneath first display port and the non-diffusively bound control reagent wil_1 be bound beneath second display port.
The results can then be interpreted. If a signal appears at the first display port and a signal appears at -the second display port, the test is positive for the presence of analyte. If there is no signal detectable at the first display port compared to the signal at the second display port, the test is negative for the presence of analyte. If there is no signal at the second display port,
The results can then be interpreted. If a signal appears at the first display port and a signal appears at -the second display port, the test is positive for the presence of analyte. If there is no signal detectable at the first display port compared to the signal at the second display port, the test is negative for the presence of analyte. If there is no signal at the second display port,
11 the user is alerted that the test results are compromised and that the test should be repeated.
Alternatively, the analytical test device can employ a competitive assay system. A diffusively bound labeled reagent capable of competing with the analyte for a non-diffusively bound reagent is applied evenly and at the same height extending from side to side of the absorbent membrane. It is applied at a downstream point spatially separated from the point where the absorbent sample pad contacts the absorbent membrane and downstream from the vertical bar. The diffusively bound labeled reagent here does not complex with the analyte. A non-diffusivel.y bound reagent that can bind either the analyze or the diffusively bound reagent is applied evenly and at the same height extending from side to side of the reaction membrane at a point beneath the display port. In this embodiment of the analytical test device, the top need only have one display port, as no comparison is required. However, if desired, a second display port may be incorporated to demonstrate the integrity of the reagents and device. In this embodiment, the presence of a visible signal, such as a straight line or bar across the reaction membrane in the display port is a validation of the assay and indicates that no analyte is present in the fluid sample. No signal in the display port: indicates the presence of analyte in the fluid sample.
The analytical test device allows the assay to be performed in simples steps. The user only has to apply the fluid sample, slide the absorbent sample pad into the receiving port to contact the absorbent sample pad with the absorbent membrane and then observe the results.
The analytical. test device is assembled by placing the absorbent membrane and the reaction membrane on the bottom
Alternatively, the analytical test device can employ a competitive assay system. A diffusively bound labeled reagent capable of competing with the analyte for a non-diffusively bound reagent is applied evenly and at the same height extending from side to side of the absorbent membrane. It is applied at a downstream point spatially separated from the point where the absorbent sample pad contacts the absorbent membrane and downstream from the vertical bar. The diffusively bound labeled reagent here does not complex with the analyte. A non-diffusivel.y bound reagent that can bind either the analyze or the diffusively bound reagent is applied evenly and at the same height extending from side to side of the reaction membrane at a point beneath the display port. In this embodiment of the analytical test device, the top need only have one display port, as no comparison is required. However, if desired, a second display port may be incorporated to demonstrate the integrity of the reagents and device. In this embodiment, the presence of a visible signal, such as a straight line or bar across the reaction membrane in the display port is a validation of the assay and indicates that no analyte is present in the fluid sample. No signal in the display port: indicates the presence of analyte in the fluid sample.
The analytical test device allows the assay to be performed in simples steps. The user only has to apply the fluid sample, slide the absorbent sample pad into the receiving port to contact the absorbent sample pad with the absorbent membrane and then observe the results.
The analytical. test device is assembled by placing the absorbent membrane and the reaction membrane on the bottom
12 and then the top :is then placed on the bottom to ensure a tight fit. One skilled in the art would understand that any suitable means to ensure a tight fit between the top and bottom can be used. For example, the top can be fitted on the bottom with snaps or glue. In addition, once the absorbent sample pad is inserted into the receiving port, the device becomes substantially fluid-tight and evaporation or leakage of the fluid sample is minimized.
To further prevent such leakage, the top and bottom are preferably made of a nonporous plastic, such as the commercially available plastic "ABS" supplied by the Monsanto Company of: St. Louis, MO.
Several features of the analytical test device assist in avoiding compromised results. First, simultaneous migration of an excessive amount of fluid sample is limited by requiring the fluid sample to ascend the slope .from the absorbent membranes to the reaction membrane. Second, the spatial separation of the diffusively bound labeled reagent on the absorbent membrane from the point at which the fluid sample first contacts the absorbent membrane ensures that the assay is not compromised by reagent leaking out into the fluid sample.. Third, the impact of leading edge effects caused by depletion of bound reagents or labels are minimized by physically separating the test and control regions, by applying the fluid sample evenly and at the same height across the absorbent membrane and by using the presence of a reaction, rather than the appearance of a given shape (such as a "+" or a "-") to signify a positive or negative result. In addition, the entire process is simplified by having the label bound to a substrate placed within the analytical test device, thus avoiding any need for the user to add a reagent or mix it with fluid sample.
As described above, the present invention is also ideally suited tc~ the application of more than one fluid
To further prevent such leakage, the top and bottom are preferably made of a nonporous plastic, such as the commercially available plastic "ABS" supplied by the Monsanto Company of: St. Louis, MO.
Several features of the analytical test device assist in avoiding compromised results. First, simultaneous migration of an excessive amount of fluid sample is limited by requiring the fluid sample to ascend the slope .from the absorbent membranes to the reaction membrane. Second, the spatial separation of the diffusively bound labeled reagent on the absorbent membrane from the point at which the fluid sample first contacts the absorbent membrane ensures that the assay is not compromised by reagent leaking out into the fluid sample.. Third, the impact of leading edge effects caused by depletion of bound reagents or labels are minimized by physically separating the test and control regions, by applying the fluid sample evenly and at the same height across the absorbent membrane and by using the presence of a reaction, rather than the appearance of a given shape (such as a "+" or a "-") to signify a positive or negative result. In addition, the entire process is simplified by having the label bound to a substrate placed within the analytical test device, thus avoiding any need for the user to add a reagent or mix it with fluid sample.
As described above, the present invention is also ideally suited tc~ the application of more than one fluid
13 sample to a single analytical test device. In prior devices, such as the one described in May et al., U.S.
Patent No. 5,602,040, issued February 11, 1997, the device (hereinafter the '040 device) is typically held in a stream of urine. The protruding sample aperture in the '040 device is in contac:i~ with the dry porous carrier inside the hollow casing of the device. Thus, the test proceeds immediately upon application of the sample. Therefore, the '040 device is su.it:ed for the testing of only one sample at a time because once the first sample is applied, the test proceeds, thereby depleting the reagents.
Moreover, since the user of the '040 device typically holds the protruding bibulous member in a urine stream, the sample is unevenly applied to the membrane. Thus, t:he '040 device suffers from leading edge effects created by an uneven solvent front along the membrane. Accordingly, reagents and bound labels could be depleted and the results could be misleading. In contrast, the user of the present analytical test device is assured that: the solvent front formed by the fluid sample will be uniform since the fluid sample is applied evenly and at the same height across the absorbent membrane. Therefore, the present analytical test device provides more reliable results.
As used herein, the terms "ligand" and "control reagent" are used interchangeably and refer to a molecule to which another molecule will bind. A ligand or control reagent can be human, animal or plant in origin. For purposes of this invention, these may include LH, hCG or other naturally occurring biological control reagents in serum, plasma, urine or other fluids and will preferably include analytes. Specifically, it will be appreciated by those skilled in the art that the control reagent or analyte may be a protein, peptide, amino acid, nucleic acid, sugar, hormone, steroid, vitamin, toxin in the sample
Patent No. 5,602,040, issued February 11, 1997, the device (hereinafter the '040 device) is typically held in a stream of urine. The protruding sample aperture in the '040 device is in contac:i~ with the dry porous carrier inside the hollow casing of the device. Thus, the test proceeds immediately upon application of the sample. Therefore, the '040 device is su.it:ed for the testing of only one sample at a time because once the first sample is applied, the test proceeds, thereby depleting the reagents.
Moreover, since the user of the '040 device typically holds the protruding bibulous member in a urine stream, the sample is unevenly applied to the membrane. Thus, t:he '040 device suffers from leading edge effects created by an uneven solvent front along the membrane. Accordingly, reagents and bound labels could be depleted and the results could be misleading. In contrast, the user of the present analytical test device is assured that: the solvent front formed by the fluid sample will be uniform since the fluid sample is applied evenly and at the same height across the absorbent membrane. Therefore, the present analytical test device provides more reliable results.
As used herein, the terms "ligand" and "control reagent" are used interchangeably and refer to a molecule to which another molecule will bind. A ligand or control reagent can be human, animal or plant in origin. For purposes of this invention, these may include LH, hCG or other naturally occurring biological control reagents in serum, plasma, urine or other fluids and will preferably include analytes. Specifically, it will be appreciated by those skilled in the art that the control reagent or analyte may be a protein, peptide, amino acid, nucleic acid, sugar, hormone, steroid, vitamin, toxin in the sample
14 fluid, pathogenic microorganism and metabolites from analogs of such analytes, or antibodies to these substances. They may also include hormones, haptens, immunoglobulin, polynucleotides, drugs and infectious disease agents (bacterial or viral) such as Streptoccus, Neisseria, Ghlarnydia, Gonorrhea and HIV.
As used herein, the term "reagent" refers to receptor molecules which bind to a control reagent. Reagents may, in this context, include any naturally occurring or synthetic biological receptor and will preferably include antibodies. The antibodies may be polyclonal or monoclonal. For simplicity, the terms antibody and analyte will be used interchangeably with reagent and control reagent, respectivE=ly, throughout this disclosure. It will be appreciated by those skilled in the art, however, that the invention is not limited to use with analytes and antibodies.
Ligand-reagent pairs useful in the present invention include specific binding pairs such as antigens and antibodies, or fraqrnents of antibodies, both polyclonal and monoclonal, lectins and carbohydrates, hormones and hormone receptors, enzymes and enzyme substrates, biotin and avidin, vitamin; and vitamin binding proteins, complementary pol.ynucleotide sequences, drugs and receptors, enzymes and inhibitors, apoproteins and cofactors, growth factors and receptors, and the like.
Biotin and avidin derivatives may also be used, including biotin analogs/avidin, biotin/streptavidin, and biotin analogs/streptavidin. Members of the complex may be "engineered," than is, made by synthetic means. Such techniques are well known in the art, and include techniques for chimeric and humanized antibodies and fragments thereo:F, synthetic peptides, and synthetic RNA
and DNA oligonuci.ectides.
Any known reagent can be used in any known format such as, for example, sandwich and competitive binding formats, to specifically detect an analyte in a fluid sample.
Examples of such reagents are those disclosed in: H. J.
5 Friesen, United States Patent No. 4,861,711, issued August 29, 1989; J. Bunting, United States Patent No. 4,271,140, issued June 2, 1981; May et al., United States Patent No.
5,622,871, issued P.pril 22., 1997; May et al., United States Patent No. 5,656,503, issued August 12, 1997; May et al., 10 United States Patent No. 5,602,040, issued February 11, 1997; and R. Rosenstein, United States Patent No.
5,591,645, issued January 7, 1997 (each of which is incorporated by reference herein). Such reagents can form a detectable complex with such control reagents as listed
As used herein, the term "reagent" refers to receptor molecules which bind to a control reagent. Reagents may, in this context, include any naturally occurring or synthetic biological receptor and will preferably include antibodies. The antibodies may be polyclonal or monoclonal. For simplicity, the terms antibody and analyte will be used interchangeably with reagent and control reagent, respectivE=ly, throughout this disclosure. It will be appreciated by those skilled in the art, however, that the invention is not limited to use with analytes and antibodies.
Ligand-reagent pairs useful in the present invention include specific binding pairs such as antigens and antibodies, or fraqrnents of antibodies, both polyclonal and monoclonal, lectins and carbohydrates, hormones and hormone receptors, enzymes and enzyme substrates, biotin and avidin, vitamin; and vitamin binding proteins, complementary pol.ynucleotide sequences, drugs and receptors, enzymes and inhibitors, apoproteins and cofactors, growth factors and receptors, and the like.
Biotin and avidin derivatives may also be used, including biotin analogs/avidin, biotin/streptavidin, and biotin analogs/streptavidin. Members of the complex may be "engineered," than is, made by synthetic means. Such techniques are well known in the art, and include techniques for chimeric and humanized antibodies and fragments thereo:F, synthetic peptides, and synthetic RNA
and DNA oligonuci.ectides.
Any known reagent can be used in any known format such as, for example, sandwich and competitive binding formats, to specifically detect an analyte in a fluid sample.
Examples of such reagents are those disclosed in: H. J.
5 Friesen, United States Patent No. 4,861,711, issued August 29, 1989; J. Bunting, United States Patent No. 4,271,140, issued June 2, 1981; May et al., United States Patent No.
5,622,871, issued P.pril 22., 1997; May et al., United States Patent No. 5,656,503, issued August 12, 1997; May et al., 10 United States Patent No. 5,602,040, issued February 11, 1997; and R. Rosenstein, United States Patent No.
5,591,645, issued January 7, 1997 (each of which is incorporated by reference herein). Such reagents can form a detectable complex with such control reagents as listed
15 above.
Preferred reagents include antibodies to a hormone or infectious disease agent. Preferred antibodies include anti-hCG antibodies and anti-human LH antibodies, especially of the IgG class, and even more so murine monoclonal antibodies and especially those that have been affinity purified. One skilled in the art would recognize, however, that pol.yclonal antibodies can also be used in the present invention.
By the term "non-diffusively bound" is meant covalent or non-covalent attachment to the absorbent membrane or reaction membrane ~;uch that the advancing fluid sample does not cause movement of the non-diffusively bound reagent or non-diffusively bound control reagent from the place it is app7.ied on these, membranes. Conversely, by the term "diffusi.vely bound" is meant placement on the absorbent membrane or reaction membrane such that the advancing fluid sample does cause movement of the diffusively bound labeled reagent from the place it is applied on these membranes.
Preferred reagents include antibodies to a hormone or infectious disease agent. Preferred antibodies include anti-hCG antibodies and anti-human LH antibodies, especially of the IgG class, and even more so murine monoclonal antibodies and especially those that have been affinity purified. One skilled in the art would recognize, however, that pol.yclonal antibodies can also be used in the present invention.
By the term "non-diffusively bound" is meant covalent or non-covalent attachment to the absorbent membrane or reaction membrane ~;uch that the advancing fluid sample does not cause movement of the non-diffusively bound reagent or non-diffusively bound control reagent from the place it is app7.ied on these, membranes. Conversely, by the term "diffusi.vely bound" is meant placement on the absorbent membrane or reaction membrane such that the advancing fluid sample does cause movement of the diffusively bound labeled reagent from the place it is applied on these membranes.
16 As used here~_n, the term "fluid sample" refers to a material suspected of containing an analyte. The fluid sample can be used directly as obtained, for example, from any biological source. The fluid sample can also be obtained from an organism and the relevant portion extracted or dissolved into a solution. For example, the fluid sample can be a physiological fluid, such as, for example, saliva, ocular lens fluid, cerebral spinal fluid, sweat, blood, pug;, mucus, serum, urine, milk, ascites fluid, synovial fluid, peritoneal fluid, amniotic fluid, and the like. In addition, the fluid sample fluid can be extracted from throat swabs, feces, or from other biological samples.
As used herein, the term "label" refers to a molecule that directly or :indirectly mediates the production of a signal (such as a color change) which is used in assay procedures to indicate the presence or absence of analyte in a fluid sample. Labels may include enzymes, fluorescent molecules and will preferably include metal sols. Labels include colored lat:ex spheres and colloidal metals. Labels include those disclosed by D. Yost et al . , United States Patent No. 4,954,452, issued September 4, 1990; J.
Leuvering, United States Patent No. 4,313,734, issued February 2 , 1982 ; P . Tarcha et al . , United States Patent No. 5,252,459, issued October 12, 1993; T. Gribnau et al., United States Patent No. 4,373,932, issued February 15, 1983; and R. Campbell, United States Patent No. 4,703,013, issued October 27, 1987 (each of which is incorporated by reference herein).
Alternatively, the label can be colored latex particles (see Campbell, U.S. Patent No. 9,703,017, issued October 27, 198'7, which is incorporated by reference herein) or can be an enzyme that has reacted with a colorless substrate to give a colored product and is
As used herein, the term "label" refers to a molecule that directly or :indirectly mediates the production of a signal (such as a color change) which is used in assay procedures to indicate the presence or absence of analyte in a fluid sample. Labels may include enzymes, fluorescent molecules and will preferably include metal sols. Labels include colored lat:ex spheres and colloidal metals. Labels include those disclosed by D. Yost et al . , United States Patent No. 4,954,452, issued September 4, 1990; J.
Leuvering, United States Patent No. 4,313,734, issued February 2 , 1982 ; P . Tarcha et al . , United States Patent No. 5,252,459, issued October 12, 1993; T. Gribnau et al., United States Patent No. 4,373,932, issued February 15, 1983; and R. Campbell, United States Patent No. 4,703,013, issued October 27, 1987 (each of which is incorporated by reference herein).
Alternatively, the label can be colored latex particles (see Campbell, U.S. Patent No. 9,703,017, issued October 27, 198'7, which is incorporated by reference herein) or can be an enzyme that has reacted with a colorless substrate to give a colored product and is
17 encapsulated, for example, in a liposome (see E. Soini, United States Patent No. 5, 518, 883, issued May 21, 1996, which is incorporated herein by reference). The label may also be an inducible property of the particles, such as colorable latex particles (see Gribnau et al., U.S. Patent No. 4,373,932, issued February 15, 1983, and de Jaeger et al., U.S. Patent Tlo. 4,837,168, issued June 6, 1989, both of which are incorporated by reference herein).
Alternatively, the label can be fluorescent molecules, such as the rhodamine, fluorescein, or umbelliferone series, employed by themselves or with a quencher molecule (see, for example, Ull.man et al., U.S. Patent No. 3,996,345, issued December '7, 1976 and Tom et al., U.S. Pat,ent No.
9,366,241, issued December 28, 1982, both of which are incorporated herein by reference). Chemiluminescent molecules, such as _L.uminol, luciferin, lucigenin, o:r oxalyl chloride can be used as a signal means (see, for example, Maier, U.S. Patent: No. 9,104,029, issued August 1., 1978, which is incorporated herein by reference). Finally, enzymatic systems 'that react with a colorless substrate to give a colored product, such as horseradish peroxidase, alkaline phosphatase, indoxyl phosphate and aminoethylcarbazole may be used as labels.
Diffusively bound complexed antibodies can be impregnated into the assay and within the absorbent membrane. The dif=fusively bound complexed antibodies are located upstream f=rom a zone on the reaction membrane of the assay that contains immobilized antibodies. The diffusively bound label complexed antibodies bind to the analyte and are carried to the zone containing the immobilized antibodies where a sandwich antibody-hormone complex is formed and detected. However, if desired, both the diffusively bound and non-diffusively bound ani=ibodies may be disposed on the same rnembrane.
zs In one embodiment, the diffusively bound labeled reagent will be labeled according to means known in the art. For purposes of producing a clearly visible reaction, labels of metal sols are preferred, with labels of colloidal gold or selenium being most preferred. An example of a su;Lt.able product is colloidal gold. These colloidal metals will produce colored reactions without addition of further reagents. However, fluorescent compounds (such as fluorescein and phycobiliprotein) and enzymes (such as those identified in U.S. Patent No.
4,275,149, which is incorporated by reference here.in), may also be used. To maximize contact of analyte with labeled reagent, the latter should be bound to the membrane across its face; i.e., From one side to the other. In addition, the labeled reagent should be bound to the membrane so that it is spatially separated from the absorbent sample pad when the absorbent sample pad is contacted with the absorbent membrane (see bar 125 shown in phantom on Figures 9, 10, 11, 12 and 1.3).
As used herein, the term "metal label" includes labels of metal sols; i.e., metal or metal compounds such as metal oxides, metal hydroxides, metal salts or polymer nuclei coated with a metal or metal compound. These meta:L labels may include dry farms of any of the above-named metals or metal compounds, an d will preferably include colloidal gold in dry form. For example, the metal label can be composed of a metal sol, a selenium sol or a carbon sol ( see, for example, Leuvering et al., U.S. Patent No. 4,:313,734, issued February 2, 1982; Moremans et al., U.S. Parent No.
4,775,636, issued October 4, 1988; Yost et al., U.S. Patent No. 4,954,452, is:>ued September 4, 1990; and Kang et al., U.S. Patent No. 5,559,041, issued September 24, 1996, each of which is incorp~arated by reference herein).
Depending on the context in which it is~ used, "reaction complex" or "complex" shall mean an a complex of analyte and diffusi.vely bound labeled reagent complex first produced in the assay ("first complex"), a complex of the first complex and the non-diffusively bound reagent produced second in the assay ("second complex"), or the second complex and the non-diffusively bound control reagent produced third in the assay ("third complex"). In another embodiment of the analytical test device, "complex"
shall mean a complex of analyte and non-diffusively bound reagent or a complex of the diffusively bound labeled reagent and non-d.if:fusively bound reagent. The complex can be made up of a lic~and-reagent pair that has spatial. and/or polar features which permit it to bind specifically to each other. By "first member" of the complex is meant the member bound, covalently or non-covalently, at least to a sub-population of t:he particles. The "second member" of a complex refers to the corresponding binding member of the pair non-diffusively bound in the control region.
The term "di~;play port" refers to any means whereby visual access to the reaction membrane can be gained. In one embodiment, a display port will be an aperture on the top positioned over the reaction membrane. The term also encompasses all or any part of the top that is made of a clear or transparent material so that the results can be seen. Thus, if the entire top is made of c:Lear or transparent material, then the entire top can be referred to as the display port. In addition, there may be a clear or transparent membrane placed between the reaction membrane and the aperture of the display port so as to prevent evaporation of fluid sample, to prevent fluid sample or other fluid from entering the display pori=, or to prevent disruption of the membranes by touching, all of which can affect t:he performance of the assay.
The term "absorbent sample pad" refers to any material capable of containing the fluid sample and when contacted with the absorbents membrane produces an even fluid front along the absorbeni~ membrane. For example, the edge of the 5 absorbent sample pad that comes into contact with the absorbent membrane should be orthoganal to the absorbent membrane, ensuring that fluid sample will be applied evenly and at the same height across the membrane, thereby producing an even fluid front. The absorbent sample pad 10 can be made from a.ny bibulous, porous or fibrous material capable of absorbing fluid rapidly. The porosity of the material can be un~_directiona.l or multidirectional. Porous plastic materials, such a polypropylene, polyethylene (preferably of high molecular weight), polyvinylidene 15 fluoride, ethylene vinylacetate, acrylonitrile and polytetrafluoro-ethylene can be used. It can be advantageous to pre-treat the pad with a surface-active agent during manufacture to reduce any inherent hydrophobicity in the pad and, therefore, enhance its 20 ability to take up and deliver a fluid sample rapidly and efficiently. The absorbent sample pad can also be made from paper or other cellulosic materials, such as nitro-cellulose. Pref=erably the material comprising the absorbent sample pad should be chosen such that the pad can be saturated with 1-_luid sample within a matter of seconds.
Also preferably, t:he material remains robust when moist, and for this reason, paper and similar materials are less preferred. In addition, by preferably providing a tight fit between the absorbent sample pad and the assembled top and bottom, the application of fluid sample to the absorbent sample pad will not result in fluid sample entering the device directly and by-passing the absorbent sample pad.
Also, the absorbent sample pad of the present invention is movable or "slidably insertable." As used herein, the term "slidably insertabl.e" refers to the ability of the absorbent sample pad to be moved inside the device. In one embodiment of the device, the absorbent sample pad is disposed between the top and the bottom and can be slid inside 'the assembled top and bottom by the user (see Figure 1) . T'he absorbent sample pad will be in an container disposed between the top and bottom in the assembled device. The container is preferably made out of the same non-porous material as the top and bottom. In another embodiment of the device, the absorbent sample pad will be initially separate from the assembled top and bottom but insertable into the receiving port. The absorbent sample pad will- preferably be complementary in shape for the receiving port such that when the absorbent sample pad is inserted into the receiving port and contacts the absorbent membrane, the analytical test device becomes substantially fluid-tight.
As used herein, the term "receiving port" refers to an aperture in the trop, o:r the bottom or optionally an aperture in the top and the bottom together that allows the absorbent sample pad to enter the assembled top and bottom and contact the absorbent membrane. Preferably, the receiving port will be complementary in size to the absorbent sample paid to ensure a tight fit.
As used herein the term "container" refers to a material capable of supporting the absorbent sample pad.
The container is preferably made of any suitable material that prevents the user from coming into direct contact with the fluid sample, which would otherwise contaminate the assay and make its use unpleasant. Specifically, the container in one ernbodiment of the invention is made of a non-porous material such as the commercially available "ABS" plastic (Monsanto Co., St. Louis, MO) comprising a top and a bottom (see Figures l, 2, 3 and 4). It is also understood that the container could be in the shape of a stick, rod or tongue depressor.
Also, as used herein the term "stopping means" refers to a structure capable of stopping the movement of the container so that the absorbent sample pad is in direct fluid flow contact with the absorbent membrane but does not allow the absorbers ~ sample pad to come into direct fluid flow contact wit:~~ the reaction membrane. In one embodiment, the a;:sembled top and bottom are the stopping means for the container. In another embodiment a horizontal bar on the bottom is the stopping means for the container.
The terms "ab;sorbent membrane" and "reaction membrane"
refer to any bibulous, porous or fibrous material capable of rapidly absorb_Lng an aqueous fluid and conducting the fluid via capillary attraction. Suitable materials are described, for example, in H. J. Friesen, United States Patent No. 9,861,'711, issued August 29, 1989; J. Bunting, United States Patent No. 4,271,140, issued June 2, 1981;
May et al., United States Patent No. 5,622,871, issued April 22, 1997; May et al., United States Patent No.
5,656,503, issued August 12, 1997; May et al., United States Patent No. 5,602,040, issued February 11, 1!x97; and R. Rosenstein, United States Patent No. 5,591,695, issued January 7, 1997 (e<~ch of which is incorporated by reference herein). The preferred material for the absorbent membrane is a fiberglass product such as that marketed as "MANNIWEB"
or "MANNIGLAS" by Lydall, Inc., Manchester, CT. Other suitable materia_Ls~ include polyethylene or nitrocellulose pads and strips. The means for binding reagents t:o these materials are we7_1-known in the art. Preferred porous materials include nitrocellulose, nylon, paper and silica gel. An advantage of a nitrocellulose membrane is that an immobilized antibody described above can be attached without prior chemical treatment. However, antibodies can be immobilized on other materials such as filter paper using well known chemical. coupling methods such as, for example, CNBr, carbonyldimidazole or tresyl chloride. The reaction membrane will preferably be a chromatographic strip coated with gelatin to enhance the life of the strip and clarity of any visible reactions produced in tree test.
The present invention also provides methods of using the analytical test: device for detecting an analyte in a fluid sample, comprising adding fluid sample to the absorbent sample pad of the analytical test device, contacting the absorbent sample pad with the absorbent membrane and obse~__°ving the reaction complex through the display port. Preferably, the reaction complex will be visible. Also preferably, there will be a first display port and a second display port.
Figure 1 shows a perspective view of one embodiment of an analytical test device for performing assays in accord with the invention. Figure 1, therefore, depicts a housing 106 of rectangular shape, although any appropriate shape may be employed. Housing 106 is composed of two parts.
The first is top 100, in which one opening appears, and the second is bottom 112. The opening through housing top 100 is display port 102 through which the test result can be viewed and comparE=_d. An opening through bottom 112 is receiving port 1~.8. Absorbent sample pad 108 is in container 126. Container 126 is preferably composed of two parts, top 128 and bottom 130.
Figure 2 is an exploded view of the analytical test device of Figure 1. In this view, it can be seen that bottom 112 contains floor 143, sidewalls 145, snaps 128 and receiving port 118. Contained within housing 106 will be membranes containing the reagents for carrying out the assay. In one embodiment there will be absorbent membrane 124 and reaction membrane 122. Absorbent membrane 124 and reaction membrane 122 will be in contact: with, but need not be affixed, to each other. In addition, they will be disposed along floor 143 in the assembled device with absorbent membrane 124 toward receiving port 118 and reaction membrane 1.22 beneath display port 102. Absorbent sample pad 108 farms a separate part of the device which can be contacted with fluid sample, and then inserted through receiving port 118 to be in fluid flow contact with absorbent membrane 124.
Figure 3 shows a perspective view of another embodiment of the analytical test device for performing assays in accord w_Lth the invention. To that end housing 207 is composed of top 208, bottom 216, and has a first display port 220 and second display port 212 positioned on top 208, preferably in close proximity for ease of comparison of results. In addition, housing 208 has receiving port 21.4. Inside container 202, will be absorbent sample pad 204. Container 202 is preferably composed of top 200 and bottom 206.
Figure 4 is an exploded view of the analytical test device shown in figure 3, and shows the components, top 208, bottom 216, lower p.l_ane 221, upper plane 240, slope 234, sidewalk 223, snaps 218, locating points 232, 242, 228 and 238, fluid gully 224, receiving port 214, and membranes containing the reagents for carrying aut the assay, as described below. To that end, it can be seen that contained within housing 207 is absorbent membrane 224, reaction membrane 222 and collecting pad 220.
Absorbent membrane 224 will be placed along lower plane 221 and along slope 234. Preferably, absorbent membrane 224 will be affixed to a nonporous substrate 226 such as vinyl 5 coated paper or plastic coated paper by an adhesive or other suitable means. Substrate 226 will extend along upper plane 240 t:o form a surface to which reaction membrane 222 will be affixed. Absorbent membrane 224 and reaction membrane 222 will be in contact with, but :need not 10 be affixed, to each other. In another embodiment, absorbent membrane 224 will be split at its point of attachment to subs>trate 226 to extend above and below the substrate. This configuration serves to regulate the flow of fluid sample from absorbent membrane 224 to :reaction 15 membrane 222. Flow control can also be enhanced by placement of a well or fluid gully 224 below the junction between membranes 224 arid 222. Figure 4 also shows the placement of absorbent sample pad 204 in container 202 between top 200 and bottom 206, which are preferably held 20 together by snap, 218. In addition, ridges 236 hold absorbent sample ~>ad 204 in place.
Figure 5 is an enlarged sectional view along .line 5-5 of the analytical test device shown in Figure 3. In this view the orientation of absorbent sample pad 204 can be 25 seen. Vertical bar 250 can be seen holding absorbent membrane 224 down to follow the contour of slope 234.
Absorbent sample pad 204 is not in fluid flow contact with absorbent membrane 224 at this point. Thus, the user has the opportunity to add additional samples or reagents if desired.
Figure 6 is another enlarged sectional view along line 5-5 of the analytical test device shown in Figure' 3. In SUBSTITUTE SHEET (RULE 261 this view absorbent sample pad 204 is in fluid flow contact with absorbent membrane 224 after having been contacted with fluid sample,, and then inserted into receiving port 214. Contact with absorbent membrane 224 will be indicated by a resistance. In this embodiment of the analytical test device, assembled top 208 and bottom 216 serve as stopping means for absorbent sample pad 204. Vertical bar 250 assures that absorlbent membrane 224 is held down so that it can contact absorbent sample pad 204.
Figure 7 shows a perspective view of another embodiment of the analytical test device. To that end, housing 306 is composed of top 300, bottom 312 and has first display part 304 and second display port 302 positioned on top 300, preferably in close proximity for ease of comparison of results. Housing 306 also has knob 314 that can be slid along groove 316 to stop point 315.
Knob 314 is connected to and controls the movement of container 3I0 containing absorbent sample pad 308.
Figure 8 is an exploded view of the analytical test device shown in E_Lgure 7 and shows the components, bottom 312, sidewalls 336, snaps 328, slope 342, upper plane 346, lower plane 343, receiving port 318, stopping means 332, locating points 334, 337, 338 and 340, fluid gully 330 and membranes containing the reagents for carrying out the assay, as described below. To that end it can be seen that contained within housing 306 is absorbent membrane 324, reaction membrane 322 and collecting pad 320. Absorbent membrane 324 will be placed along lower plane 343 and along slope 342. Preferably, absorbent membrane 324 will be affixed to a nonporous substrate 326 such as vinyl coated paper or plastic coated paper by an adhesive or other suitable means. Substrate 326 will extend along upper SUBSTITUTE SHEET (RULE 26) plane 346 to form a surface to which reaction membrane 322 will be affixed. Absorbent membrane 324 and reaction membrane 322 will be in contact with, but need not be affixed, to each other. In another embodiment, absorbent membrane 324 will be split at its point of attachment to substrate 326 to extend above and below the substrate.
This configuration serves to regulate flow of fluid sample from absorbent mernb~rane 324 to reaction membrane 322. Flow control can also be enhanced by placement of a well or fluid gully 330 below the junction between membranes 324 and 322.
Figure 9 is an enlarged sectional view along line 9-9 of the analytical test device shown in Figure 7. In this view the orientat.:Lon of absorbent sample container 310, absorbent sample pad 308 and absorbent membrane 324 can be seen. Vertical bar 350 extends downward from the top and holds absorbent membrane 324 along slope 342. Stopping means 332 can al~;o be seen. Fluid sample is added to absorbent sample pad 308. It can be seen that absorbent sample pad 308 is not in fluid flow contact with absorbent membrane 324 at this point. Thus, the user has the opportunity to add additional samples or reagents if desired.
Figure 10 is another enlarged sectional view along line 9-9 of the analytical test device shown in Figure 7.
It can be seen that absorbent sample pad 308 is :in fluid flow contact with absorbent membrane 324 at this point, having been stopped by stopping means 332.
In Figures 11, 12 and 13, analyte in the fluid sample, if present, will bind to the diffusively bound labeled reagent at point 425 on absorbent membrane 424 to form a SUBSTITUTE SHEET (RULE 261 first complex. I:~ desired, further fluid sample may be added up to the maximum binding capacity of unlabeled reagent and absorbency of the collecting pad material 420.
The first complex and unbound first reagent, if any, will be carried along with the fluid sample by capillary action up to the reaction. membrane 422. The position of the non-diffusively bound labeled reagent and first complex, if any, are indicated as 425 on Figures 11, 12 and 13.
All first complexes carried with the fluid sample will contact the reaction membrane 422. Fluid sample will pass through the reaction membrane 422, bringing the first complex, if any, into contact with the non-diffusively bound reagent to the reaction membrane 422 t:o bind therewith to form a second complex composed o.f first complex/non-diffusively bound reagent. If second complexes are formed, they will appear in the test region 427 (Figure 12) .
Fluid sample will continue its migration by wicking through reaction membrane 422 past the non-diff_usively bound reagent to the non-diffusively bound control reagent.
Diffusively bound .Labeled reagent not complexed to analyte will bind with the non-diffusively bound control reagent to form a third complex. The third complex will appear as display 421 in the control region (Figures 11, 12 and 13).
Substrate 426 is also shown.
Formation of all complexes in the assay method described herein may be by sandwich or competitive immunoassay techniques well known to those skilled in the art. Within a predetermined time period, any second complex present and the third complex will produce a detectable signal. mediated by the label. In one embodiment, the dErtectab.Le signal will be a color change.
This color change will signal either a positive (analyte present) or negative (analyte not present) reaction by providing two separate reactive regions within those portions of reaction membrane 422 visible to the user through the display ports.
Other control or comparative result signals may be provided, including signals that indicate whether an invalid result is obtained, by similar means known t.o those skilled in the arl~ (see, for example, the signal system described in Brown et al., United States Patent No.
5,160,701, issued November 3, 1992, which is incorporated by reference herein).
As shown in Figure 11, a positive result is indicated when color changes forming substantially similar shapes (in this instance, horizontal bars 421 and 423) appear. In contrast, as shown in Figure 12, a negative result is indicated when a color change forming a distinguishable shape only appears, for example, as a horizontal bar 421.
Finally, an incon~~lusive result is shown in Figure 13, where color changes appear in both regions having substantially dissimilar shapes (i.e., horizontal bar 421 and smudge 429). In this latter instance, the user would be alerted that the test should be repeated. While due to the decreased impact of leading edge effects and similar phenomena in th_Ls assay it is not expected that inconclusive results will be frequent, the assay requires such a small appl:ication of fluid sample that repetition should not be problematic: in most applications.
Figure 14 and Figure 15 show perspective views of the absorbent and reaction membranes wherein a competitive assay is employed. Figure 14 shows a positive assay result, as indicated by no signal in the display port.
Figure 15 shows a negative assay result, as indicated by the presence of bar 452 in the display port.
EXAMPLE I
Analytical Test De~~ce with Separate Absorbent Sample Pad 5 This example describes the method and analytical test device depicted in Figure 3 containing a separate absorbent sample pad that is inserted into the receiving port:.
This assay procedure is performed using anti-hCG
antibody to form the second complex and an 10 anti-hCG-colloidal gold compound to form the first complex.
A fluid sample can be collected at any time of day, but for best results, it i_s best to test the first urine of the morning because it contains the highest concentration of hCG. The fluid sample is 1 cubic centimeter (hereinafter 15 "cc") of urine suspected of containing hCG; the assay is performed at amb:Lent temperatures not below 1.5°C or exceeding 30°C. Absorbent sample pad 204 is placed into contact with a sample of urine, either by dipping it into a container containing at least 1 cc of urine, or by 20 holding container 202 containing absorbent sample pad 204 into a stream of urine. Absorbent sample pad 204 is then inserted into receiving port 214 so that absorbent sample pad contacts absorbent membrane 224. Within 3 minutes visible color changes, (from pure white to pink) through 25 substantially the center of display ports 210 and 212 on reaction membrane 222, are faintly visible. By the end of five minutes, a vividly pink bar symbol has appeared through substant_La.l_ly the center of each display port, indicating the presence of hCG in the fluid sample. All 30 other visible areas of the reaction membrane visible through the second display port remain white, which is the normally visible color of the reaction membrane. This assay may be performed at any time after a suspected conception to determine the presence of hCG and, therefore, pregnancy.
EXAMPLE II
Analytical Test Device with Co,~tainer Disposed Between ~o_~~ and Bottom of Device This example describes the method and analytical test device depicted in Figure 7 containing a absorbent sample pad and container disposed between the top and bottom of the device.
The assay procedure is performed using anti-hCG
antibody to form the second complex and an anti-hCG-colloidal. gold compound to form the first complex.
A fluid sample can be collected at any time of day, but for best results, it i~> best to test the first urine of the morning because it contains the highest concentration of hCG. The fluid sample is at least 1 cubic centimeter (hereinafter "cc") of urine suspected of containing hCG;
the assay is performed at ambient temperatures not below 15°C or exceeding X30°C. The 1 cc of urine is added to absorbent sample pa.d 308 by pipette. The container 310 is slid using knob 31.4 along groove 316 to its stop position 315. Within 3 minutes visible color changes, (from pure white to pink) thrc>ugh substantially the center of display ports 304 and 302 on reaction membrane 322, are faintly visible. By the end of five minutes, a vividly pink bar symbol has appearesd through substantially the center of each display port, indicating the presence of hCG in the sample. All other visible areas of the reaction membrane visible through the second display port remain white., which WO 00/17626 PC'f/US98/27705 is the normally visible color of the reaction membrane.
This assay may be performed at any time after a suspected conception to determine the presence of hCG and, therefore, pregnancy.
Although the invention has been described with reference to the examples provided above, it should be understood that various modifications can be made without departing from the spirit of the invention. Accordingly, the invention is limited only by the claims.
Alternatively, the label can be fluorescent molecules, such as the rhodamine, fluorescein, or umbelliferone series, employed by themselves or with a quencher molecule (see, for example, Ull.man et al., U.S. Patent No. 3,996,345, issued December '7, 1976 and Tom et al., U.S. Pat,ent No.
9,366,241, issued December 28, 1982, both of which are incorporated herein by reference). Chemiluminescent molecules, such as _L.uminol, luciferin, lucigenin, o:r oxalyl chloride can be used as a signal means (see, for example, Maier, U.S. Patent: No. 9,104,029, issued August 1., 1978, which is incorporated herein by reference). Finally, enzymatic systems 'that react with a colorless substrate to give a colored product, such as horseradish peroxidase, alkaline phosphatase, indoxyl phosphate and aminoethylcarbazole may be used as labels.
Diffusively bound complexed antibodies can be impregnated into the assay and within the absorbent membrane. The dif=fusively bound complexed antibodies are located upstream f=rom a zone on the reaction membrane of the assay that contains immobilized antibodies. The diffusively bound label complexed antibodies bind to the analyte and are carried to the zone containing the immobilized antibodies where a sandwich antibody-hormone complex is formed and detected. However, if desired, both the diffusively bound and non-diffusively bound ani=ibodies may be disposed on the same rnembrane.
zs In one embodiment, the diffusively bound labeled reagent will be labeled according to means known in the art. For purposes of producing a clearly visible reaction, labels of metal sols are preferred, with labels of colloidal gold or selenium being most preferred. An example of a su;Lt.able product is colloidal gold. These colloidal metals will produce colored reactions without addition of further reagents. However, fluorescent compounds (such as fluorescein and phycobiliprotein) and enzymes (such as those identified in U.S. Patent No.
4,275,149, which is incorporated by reference here.in), may also be used. To maximize contact of analyte with labeled reagent, the latter should be bound to the membrane across its face; i.e., From one side to the other. In addition, the labeled reagent should be bound to the membrane so that it is spatially separated from the absorbent sample pad when the absorbent sample pad is contacted with the absorbent membrane (see bar 125 shown in phantom on Figures 9, 10, 11, 12 and 1.3).
As used herein, the term "metal label" includes labels of metal sols; i.e., metal or metal compounds such as metal oxides, metal hydroxides, metal salts or polymer nuclei coated with a metal or metal compound. These meta:L labels may include dry farms of any of the above-named metals or metal compounds, an d will preferably include colloidal gold in dry form. For example, the metal label can be composed of a metal sol, a selenium sol or a carbon sol ( see, for example, Leuvering et al., U.S. Patent No. 4,:313,734, issued February 2, 1982; Moremans et al., U.S. Parent No.
4,775,636, issued October 4, 1988; Yost et al., U.S. Patent No. 4,954,452, is:>ued September 4, 1990; and Kang et al., U.S. Patent No. 5,559,041, issued September 24, 1996, each of which is incorp~arated by reference herein).
Depending on the context in which it is~ used, "reaction complex" or "complex" shall mean an a complex of analyte and diffusi.vely bound labeled reagent complex first produced in the assay ("first complex"), a complex of the first complex and the non-diffusively bound reagent produced second in the assay ("second complex"), or the second complex and the non-diffusively bound control reagent produced third in the assay ("third complex"). In another embodiment of the analytical test device, "complex"
shall mean a complex of analyte and non-diffusively bound reagent or a complex of the diffusively bound labeled reagent and non-d.if:fusively bound reagent. The complex can be made up of a lic~and-reagent pair that has spatial. and/or polar features which permit it to bind specifically to each other. By "first member" of the complex is meant the member bound, covalently or non-covalently, at least to a sub-population of t:he particles. The "second member" of a complex refers to the corresponding binding member of the pair non-diffusively bound in the control region.
The term "di~;play port" refers to any means whereby visual access to the reaction membrane can be gained. In one embodiment, a display port will be an aperture on the top positioned over the reaction membrane. The term also encompasses all or any part of the top that is made of a clear or transparent material so that the results can be seen. Thus, if the entire top is made of c:Lear or transparent material, then the entire top can be referred to as the display port. In addition, there may be a clear or transparent membrane placed between the reaction membrane and the aperture of the display port so as to prevent evaporation of fluid sample, to prevent fluid sample or other fluid from entering the display pori=, or to prevent disruption of the membranes by touching, all of which can affect t:he performance of the assay.
The term "absorbent sample pad" refers to any material capable of containing the fluid sample and when contacted with the absorbents membrane produces an even fluid front along the absorbeni~ membrane. For example, the edge of the 5 absorbent sample pad that comes into contact with the absorbent membrane should be orthoganal to the absorbent membrane, ensuring that fluid sample will be applied evenly and at the same height across the membrane, thereby producing an even fluid front. The absorbent sample pad 10 can be made from a.ny bibulous, porous or fibrous material capable of absorbing fluid rapidly. The porosity of the material can be un~_directiona.l or multidirectional. Porous plastic materials, such a polypropylene, polyethylene (preferably of high molecular weight), polyvinylidene 15 fluoride, ethylene vinylacetate, acrylonitrile and polytetrafluoro-ethylene can be used. It can be advantageous to pre-treat the pad with a surface-active agent during manufacture to reduce any inherent hydrophobicity in the pad and, therefore, enhance its 20 ability to take up and deliver a fluid sample rapidly and efficiently. The absorbent sample pad can also be made from paper or other cellulosic materials, such as nitro-cellulose. Pref=erably the material comprising the absorbent sample pad should be chosen such that the pad can be saturated with 1-_luid sample within a matter of seconds.
Also preferably, t:he material remains robust when moist, and for this reason, paper and similar materials are less preferred. In addition, by preferably providing a tight fit between the absorbent sample pad and the assembled top and bottom, the application of fluid sample to the absorbent sample pad will not result in fluid sample entering the device directly and by-passing the absorbent sample pad.
Also, the absorbent sample pad of the present invention is movable or "slidably insertable." As used herein, the term "slidably insertabl.e" refers to the ability of the absorbent sample pad to be moved inside the device. In one embodiment of the device, the absorbent sample pad is disposed between the top and the bottom and can be slid inside 'the assembled top and bottom by the user (see Figure 1) . T'he absorbent sample pad will be in an container disposed between the top and bottom in the assembled device. The container is preferably made out of the same non-porous material as the top and bottom. In another embodiment of the device, the absorbent sample pad will be initially separate from the assembled top and bottom but insertable into the receiving port. The absorbent sample pad will- preferably be complementary in shape for the receiving port such that when the absorbent sample pad is inserted into the receiving port and contacts the absorbent membrane, the analytical test device becomes substantially fluid-tight.
As used herein, the term "receiving port" refers to an aperture in the trop, o:r the bottom or optionally an aperture in the top and the bottom together that allows the absorbent sample pad to enter the assembled top and bottom and contact the absorbent membrane. Preferably, the receiving port will be complementary in size to the absorbent sample paid to ensure a tight fit.
As used herein the term "container" refers to a material capable of supporting the absorbent sample pad.
The container is preferably made of any suitable material that prevents the user from coming into direct contact with the fluid sample, which would otherwise contaminate the assay and make its use unpleasant. Specifically, the container in one ernbodiment of the invention is made of a non-porous material such as the commercially available "ABS" plastic (Monsanto Co., St. Louis, MO) comprising a top and a bottom (see Figures l, 2, 3 and 4). It is also understood that the container could be in the shape of a stick, rod or tongue depressor.
Also, as used herein the term "stopping means" refers to a structure capable of stopping the movement of the container so that the absorbent sample pad is in direct fluid flow contact with the absorbent membrane but does not allow the absorbers ~ sample pad to come into direct fluid flow contact wit:~~ the reaction membrane. In one embodiment, the a;:sembled top and bottom are the stopping means for the container. In another embodiment a horizontal bar on the bottom is the stopping means for the container.
The terms "ab;sorbent membrane" and "reaction membrane"
refer to any bibulous, porous or fibrous material capable of rapidly absorb_Lng an aqueous fluid and conducting the fluid via capillary attraction. Suitable materials are described, for example, in H. J. Friesen, United States Patent No. 9,861,'711, issued August 29, 1989; J. Bunting, United States Patent No. 4,271,140, issued June 2, 1981;
May et al., United States Patent No. 5,622,871, issued April 22, 1997; May et al., United States Patent No.
5,656,503, issued August 12, 1997; May et al., United States Patent No. 5,602,040, issued February 11, 1!x97; and R. Rosenstein, United States Patent No. 5,591,695, issued January 7, 1997 (e<~ch of which is incorporated by reference herein). The preferred material for the absorbent membrane is a fiberglass product such as that marketed as "MANNIWEB"
or "MANNIGLAS" by Lydall, Inc., Manchester, CT. Other suitable materia_Ls~ include polyethylene or nitrocellulose pads and strips. The means for binding reagents t:o these materials are we7_1-known in the art. Preferred porous materials include nitrocellulose, nylon, paper and silica gel. An advantage of a nitrocellulose membrane is that an immobilized antibody described above can be attached without prior chemical treatment. However, antibodies can be immobilized on other materials such as filter paper using well known chemical. coupling methods such as, for example, CNBr, carbonyldimidazole or tresyl chloride. The reaction membrane will preferably be a chromatographic strip coated with gelatin to enhance the life of the strip and clarity of any visible reactions produced in tree test.
The present invention also provides methods of using the analytical test: device for detecting an analyte in a fluid sample, comprising adding fluid sample to the absorbent sample pad of the analytical test device, contacting the absorbent sample pad with the absorbent membrane and obse~__°ving the reaction complex through the display port. Preferably, the reaction complex will be visible. Also preferably, there will be a first display port and a second display port.
Figure 1 shows a perspective view of one embodiment of an analytical test device for performing assays in accord with the invention. Figure 1, therefore, depicts a housing 106 of rectangular shape, although any appropriate shape may be employed. Housing 106 is composed of two parts.
The first is top 100, in which one opening appears, and the second is bottom 112. The opening through housing top 100 is display port 102 through which the test result can be viewed and comparE=_d. An opening through bottom 112 is receiving port 1~.8. Absorbent sample pad 108 is in container 126. Container 126 is preferably composed of two parts, top 128 and bottom 130.
Figure 2 is an exploded view of the analytical test device of Figure 1. In this view, it can be seen that bottom 112 contains floor 143, sidewalls 145, snaps 128 and receiving port 118. Contained within housing 106 will be membranes containing the reagents for carrying out the assay. In one embodiment there will be absorbent membrane 124 and reaction membrane 122. Absorbent membrane 124 and reaction membrane 122 will be in contact: with, but need not be affixed, to each other. In addition, they will be disposed along floor 143 in the assembled device with absorbent membrane 124 toward receiving port 118 and reaction membrane 1.22 beneath display port 102. Absorbent sample pad 108 farms a separate part of the device which can be contacted with fluid sample, and then inserted through receiving port 118 to be in fluid flow contact with absorbent membrane 124.
Figure 3 shows a perspective view of another embodiment of the analytical test device for performing assays in accord w_Lth the invention. To that end housing 207 is composed of top 208, bottom 216, and has a first display port 220 and second display port 212 positioned on top 208, preferably in close proximity for ease of comparison of results. In addition, housing 208 has receiving port 21.4. Inside container 202, will be absorbent sample pad 204. Container 202 is preferably composed of top 200 and bottom 206.
Figure 4 is an exploded view of the analytical test device shown in figure 3, and shows the components, top 208, bottom 216, lower p.l_ane 221, upper plane 240, slope 234, sidewalk 223, snaps 218, locating points 232, 242, 228 and 238, fluid gully 224, receiving port 214, and membranes containing the reagents for carrying aut the assay, as described below. To that end, it can be seen that contained within housing 207 is absorbent membrane 224, reaction membrane 222 and collecting pad 220.
Absorbent membrane 224 will be placed along lower plane 221 and along slope 234. Preferably, absorbent membrane 224 will be affixed to a nonporous substrate 226 such as vinyl 5 coated paper or plastic coated paper by an adhesive or other suitable means. Substrate 226 will extend along upper plane 240 t:o form a surface to which reaction membrane 222 will be affixed. Absorbent membrane 224 and reaction membrane 222 will be in contact with, but :need not 10 be affixed, to each other. In another embodiment, absorbent membrane 224 will be split at its point of attachment to subs>trate 226 to extend above and below the substrate. This configuration serves to regulate the flow of fluid sample from absorbent membrane 224 to :reaction 15 membrane 222. Flow control can also be enhanced by placement of a well or fluid gully 224 below the junction between membranes 224 arid 222. Figure 4 also shows the placement of absorbent sample pad 204 in container 202 between top 200 and bottom 206, which are preferably held 20 together by snap, 218. In addition, ridges 236 hold absorbent sample ~>ad 204 in place.
Figure 5 is an enlarged sectional view along .line 5-5 of the analytical test device shown in Figure 3. In this view the orientation of absorbent sample pad 204 can be 25 seen. Vertical bar 250 can be seen holding absorbent membrane 224 down to follow the contour of slope 234.
Absorbent sample pad 204 is not in fluid flow contact with absorbent membrane 224 at this point. Thus, the user has the opportunity to add additional samples or reagents if desired.
Figure 6 is another enlarged sectional view along line 5-5 of the analytical test device shown in Figure' 3. In SUBSTITUTE SHEET (RULE 261 this view absorbent sample pad 204 is in fluid flow contact with absorbent membrane 224 after having been contacted with fluid sample,, and then inserted into receiving port 214. Contact with absorbent membrane 224 will be indicated by a resistance. In this embodiment of the analytical test device, assembled top 208 and bottom 216 serve as stopping means for absorbent sample pad 204. Vertical bar 250 assures that absorlbent membrane 224 is held down so that it can contact absorbent sample pad 204.
Figure 7 shows a perspective view of another embodiment of the analytical test device. To that end, housing 306 is composed of top 300, bottom 312 and has first display part 304 and second display port 302 positioned on top 300, preferably in close proximity for ease of comparison of results. Housing 306 also has knob 314 that can be slid along groove 316 to stop point 315.
Knob 314 is connected to and controls the movement of container 3I0 containing absorbent sample pad 308.
Figure 8 is an exploded view of the analytical test device shown in E_Lgure 7 and shows the components, bottom 312, sidewalls 336, snaps 328, slope 342, upper plane 346, lower plane 343, receiving port 318, stopping means 332, locating points 334, 337, 338 and 340, fluid gully 330 and membranes containing the reagents for carrying out the assay, as described below. To that end it can be seen that contained within housing 306 is absorbent membrane 324, reaction membrane 322 and collecting pad 320. Absorbent membrane 324 will be placed along lower plane 343 and along slope 342. Preferably, absorbent membrane 324 will be affixed to a nonporous substrate 326 such as vinyl coated paper or plastic coated paper by an adhesive or other suitable means. Substrate 326 will extend along upper SUBSTITUTE SHEET (RULE 26) plane 346 to form a surface to which reaction membrane 322 will be affixed. Absorbent membrane 324 and reaction membrane 322 will be in contact with, but need not be affixed, to each other. In another embodiment, absorbent membrane 324 will be split at its point of attachment to substrate 326 to extend above and below the substrate.
This configuration serves to regulate flow of fluid sample from absorbent mernb~rane 324 to reaction membrane 322. Flow control can also be enhanced by placement of a well or fluid gully 330 below the junction between membranes 324 and 322.
Figure 9 is an enlarged sectional view along line 9-9 of the analytical test device shown in Figure 7. In this view the orientat.:Lon of absorbent sample container 310, absorbent sample pad 308 and absorbent membrane 324 can be seen. Vertical bar 350 extends downward from the top and holds absorbent membrane 324 along slope 342. Stopping means 332 can al~;o be seen. Fluid sample is added to absorbent sample pad 308. It can be seen that absorbent sample pad 308 is not in fluid flow contact with absorbent membrane 324 at this point. Thus, the user has the opportunity to add additional samples or reagents if desired.
Figure 10 is another enlarged sectional view along line 9-9 of the analytical test device shown in Figure 7.
It can be seen that absorbent sample pad 308 is :in fluid flow contact with absorbent membrane 324 at this point, having been stopped by stopping means 332.
In Figures 11, 12 and 13, analyte in the fluid sample, if present, will bind to the diffusively bound labeled reagent at point 425 on absorbent membrane 424 to form a SUBSTITUTE SHEET (RULE 261 first complex. I:~ desired, further fluid sample may be added up to the maximum binding capacity of unlabeled reagent and absorbency of the collecting pad material 420.
The first complex and unbound first reagent, if any, will be carried along with the fluid sample by capillary action up to the reaction. membrane 422. The position of the non-diffusively bound labeled reagent and first complex, if any, are indicated as 425 on Figures 11, 12 and 13.
All first complexes carried with the fluid sample will contact the reaction membrane 422. Fluid sample will pass through the reaction membrane 422, bringing the first complex, if any, into contact with the non-diffusively bound reagent to the reaction membrane 422 t:o bind therewith to form a second complex composed o.f first complex/non-diffusively bound reagent. If second complexes are formed, they will appear in the test region 427 (Figure 12) .
Fluid sample will continue its migration by wicking through reaction membrane 422 past the non-diff_usively bound reagent to the non-diffusively bound control reagent.
Diffusively bound .Labeled reagent not complexed to analyte will bind with the non-diffusively bound control reagent to form a third complex. The third complex will appear as display 421 in the control region (Figures 11, 12 and 13).
Substrate 426 is also shown.
Formation of all complexes in the assay method described herein may be by sandwich or competitive immunoassay techniques well known to those skilled in the art. Within a predetermined time period, any second complex present and the third complex will produce a detectable signal. mediated by the label. In one embodiment, the dErtectab.Le signal will be a color change.
This color change will signal either a positive (analyte present) or negative (analyte not present) reaction by providing two separate reactive regions within those portions of reaction membrane 422 visible to the user through the display ports.
Other control or comparative result signals may be provided, including signals that indicate whether an invalid result is obtained, by similar means known t.o those skilled in the arl~ (see, for example, the signal system described in Brown et al., United States Patent No.
5,160,701, issued November 3, 1992, which is incorporated by reference herein).
As shown in Figure 11, a positive result is indicated when color changes forming substantially similar shapes (in this instance, horizontal bars 421 and 423) appear. In contrast, as shown in Figure 12, a negative result is indicated when a color change forming a distinguishable shape only appears, for example, as a horizontal bar 421.
Finally, an incon~~lusive result is shown in Figure 13, where color changes appear in both regions having substantially dissimilar shapes (i.e., horizontal bar 421 and smudge 429). In this latter instance, the user would be alerted that the test should be repeated. While due to the decreased impact of leading edge effects and similar phenomena in th_Ls assay it is not expected that inconclusive results will be frequent, the assay requires such a small appl:ication of fluid sample that repetition should not be problematic: in most applications.
Figure 14 and Figure 15 show perspective views of the absorbent and reaction membranes wherein a competitive assay is employed. Figure 14 shows a positive assay result, as indicated by no signal in the display port.
Figure 15 shows a negative assay result, as indicated by the presence of bar 452 in the display port.
EXAMPLE I
Analytical Test De~~ce with Separate Absorbent Sample Pad 5 This example describes the method and analytical test device depicted in Figure 3 containing a separate absorbent sample pad that is inserted into the receiving port:.
This assay procedure is performed using anti-hCG
antibody to form the second complex and an 10 anti-hCG-colloidal gold compound to form the first complex.
A fluid sample can be collected at any time of day, but for best results, it i_s best to test the first urine of the morning because it contains the highest concentration of hCG. The fluid sample is 1 cubic centimeter (hereinafter 15 "cc") of urine suspected of containing hCG; the assay is performed at amb:Lent temperatures not below 1.5°C or exceeding 30°C. Absorbent sample pad 204 is placed into contact with a sample of urine, either by dipping it into a container containing at least 1 cc of urine, or by 20 holding container 202 containing absorbent sample pad 204 into a stream of urine. Absorbent sample pad 204 is then inserted into receiving port 214 so that absorbent sample pad contacts absorbent membrane 224. Within 3 minutes visible color changes, (from pure white to pink) through 25 substantially the center of display ports 210 and 212 on reaction membrane 222, are faintly visible. By the end of five minutes, a vividly pink bar symbol has appeared through substant_La.l_ly the center of each display port, indicating the presence of hCG in the fluid sample. All 30 other visible areas of the reaction membrane visible through the second display port remain white, which is the normally visible color of the reaction membrane. This assay may be performed at any time after a suspected conception to determine the presence of hCG and, therefore, pregnancy.
EXAMPLE II
Analytical Test Device with Co,~tainer Disposed Between ~o_~~ and Bottom of Device This example describes the method and analytical test device depicted in Figure 7 containing a absorbent sample pad and container disposed between the top and bottom of the device.
The assay procedure is performed using anti-hCG
antibody to form the second complex and an anti-hCG-colloidal. gold compound to form the first complex.
A fluid sample can be collected at any time of day, but for best results, it i~> best to test the first urine of the morning because it contains the highest concentration of hCG. The fluid sample is at least 1 cubic centimeter (hereinafter "cc") of urine suspected of containing hCG;
the assay is performed at ambient temperatures not below 15°C or exceeding X30°C. The 1 cc of urine is added to absorbent sample pa.d 308 by pipette. The container 310 is slid using knob 31.4 along groove 316 to its stop position 315. Within 3 minutes visible color changes, (from pure white to pink) thrc>ugh substantially the center of display ports 304 and 302 on reaction membrane 322, are faintly visible. By the end of five minutes, a vividly pink bar symbol has appearesd through substantially the center of each display port, indicating the presence of hCG in the sample. All other visible areas of the reaction membrane visible through the second display port remain white., which WO 00/17626 PC'f/US98/27705 is the normally visible color of the reaction membrane.
This assay may be performed at any time after a suspected conception to determine the presence of hCG and, therefore, pregnancy.
Although the invention has been described with reference to the examples provided above, it should be understood that various modifications can be made without departing from the spirit of the invention. Accordingly, the invention is limited only by the claims.
Claims (14)
1. An analytical test device, comprising a housing comprising:
(a) a top having one or more display ports;
(b) a bottom;
(I) the top or the bottom further having a receiving port or together the top and the bottom forming a receiving port for receiving a container comprising an absorbent sample receiving pad;
(c) a test strip comprising an absorbent membrane, a reaction membrane having one or more reagents that form a reaction complex with an analyte in a fluid sample;
(d) an absorbent receiving sample pad in a container; and (e) a stopping means, wherein the absorbent membrane and the reaction membrane axe in fluid flow contact with one another;
the strip is placed in the bottom such that the reaction membrane is visible thorough the one or more display ports and the absorbent membrane is towards the receiving port:
and in the assembled top and bottom, the absorbent sample receiving pad is slidably insertable through the receiving port until further insertion is stopped by the stopping means, which places the absorbent sample receiving pad in fluid flow contact with the absorbent membrane.
(a) a top having one or more display ports;
(b) a bottom;
(I) the top or the bottom further having a receiving port or together the top and the bottom forming a receiving port for receiving a container comprising an absorbent sample receiving pad;
(c) a test strip comprising an absorbent membrane, a reaction membrane having one or more reagents that form a reaction complex with an analyte in a fluid sample;
(d) an absorbent receiving sample pad in a container; and (e) a stopping means, wherein the absorbent membrane and the reaction membrane axe in fluid flow contact with one another;
the strip is placed in the bottom such that the reaction membrane is visible thorough the one or more display ports and the absorbent membrane is towards the receiving port:
and in the assembled top and bottom, the absorbent sample receiving pad is slidably insertable through the receiving port until further insertion is stopped by the stopping means, which places the absorbent sample receiving pad in fluid flow contact with the absorbent membrane.
2. The analytical test device of claim 1, wherein the bottom further comprises a slope with an upper and lower end, an upper plane attached to the upper end of the slope, and a lower plane attached to the lower end of the slope.
3. The analytical test device of claim 2, wherein the top further comprises a vertical bar that deflects the absorbent membrane to follow the contour of the slope.
4. The analytical test device of claim 1, wherein the stopping means is the container contacting the outside of the assembled top and bottom at the receiving port.
5. The analytical test device of claim 1, wherein the bottom further comprises a horizontal bar inside the assembled top and bottom and is the stopping means.
5. The analytical test device of claim 1, wherein the bottom further comprises a horizontal bar inside the assembled top and bottom and is the stopping means.
5. The analytical test device of claim 5, wherein the stopping means is the horizontal bar contacting the container.
35
7. The analytical test device of claim 1, wherein an end of the absorbent sample receiving pad that contacts the absorbent membrane is orthogonal to the absorbent membrane.
8. The analytical test device of claim 1, further containing one or more labeled reagents which migrate with the sample and axe deposited on the absorbent membrane at a point spatially separated from the point at which the absorbent sample receiving pad first contacts the absorbent membrane.
9. The analytical test device of claim 8, wherein immobilized to the reaction membrane is:
(a) an immobilized reagent complementary to an analyte in the fluid sample at a point beneath a first display port; and (b) an immobilized control reagent complementary to the labeled reagent at a point beneath a second display port.
(a) an immobilized reagent complementary to an analyte in the fluid sample at a point beneath a first display port; and (b) an immobilized control reagent complementary to the labeled reagent at a point beneath a second display port.
10. The analytical test device of claim 8, wherein bound to the reaction membrane at a point beneath a first display port is an immobilized reagent, wherein the analyte and the labeled reagent compete for binding to the immobilised reagent, or wherein the immobilized reagent and the analyte compete for binding to the labeled reagent.
11. A method for detecting an analyte in a fluid sample, comprising the steps of:
(a) adding the fluid sample to the absorbent sample receiving pad of the analytical test device of claim 1;
(b) inserting the absorbent sample receiving pad into the receiving port until the absorbent sample receiving pad is stopped by the stopping means;
(c) detecting the analyte by observing a reaction complex through the one or more display ports.
(a) adding the fluid sample to the absorbent sample receiving pad of the analytical test device of claim 1;
(b) inserting the absorbent sample receiving pad into the receiving port until the absorbent sample receiving pad is stopped by the stopping means;
(c) detecting the analyte by observing a reaction complex through the one or more display ports.
12. The method according to claim 11, wherein the reaction complex is visible.
13. The analytical device of claim 1, further comprising a groove along one side of the housing and a knob connected to said container, wherein said knob slides along said groove to control movement of said container in said housing.
14. A method for detecting an analyte in a fluid sample using the device of claim 13, comprising the steps of:
(a) sliding the container comprising the absorbent sample receiving pad into a position for receiving a sample;
(b) adding fluid sample to the absorbent sample receiving pad;
(c) sliding the container comprising the absorbent sample receiving pad into a position in fluid flow contact with the absorbent membrane;
(d) detecting the analyte by observing a reaction complex through the one or more display ports.
(a) sliding the container comprising the absorbent sample receiving pad into a position for receiving a sample;
(b) adding fluid sample to the absorbent sample receiving pad;
(c) sliding the container comprising the absorbent sample receiving pad into a position in fluid flow contact with the absorbent membrane;
(d) detecting the analyte by observing a reaction complex through the one or more display ports.
Applications Claiming Priority (3)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US09/156,770 | 1998-09-18 | ||
US09/156,770 US6140136A (en) | 1998-09-18 | 1998-09-18 | Analytical test device and method of use |
PCT/US1998/027705 WO2000017626A1 (en) | 1998-09-18 | 1998-12-29 | Analytical test device and method of use |
Publications (1)
Publication Number | Publication Date |
---|---|
CA2344453A1 true CA2344453A1 (en) | 2000-03-30 |
Family
ID=22561015
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
CA002344453A Abandoned CA2344453A1 (en) | 1998-09-18 | 1998-12-29 | Analytical test device and method of use |
Country Status (9)
Country | Link |
---|---|
US (2) | US6140136A (en) |
EP (1) | EP1003037B1 (en) |
AT (1) | ATE208498T1 (en) |
AU (1) | AU770689B2 (en) |
CA (1) | CA2344453A1 (en) |
DE (1) | DE69802412T2 (en) |
GB (1) | GB2342993A (en) |
TW (1) | TW459126B (en) |
WO (1) | WO2000017626A1 (en) |
Families Citing this family (107)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
DE69732131T2 (en) * | 1996-10-25 | 2005-12-15 | Idexx Laboratories, Inc. | Immuno-assay device with divisible housing |
EP1086372B1 (en) * | 1998-03-30 | 2006-05-31 | OraSure Technologies, Inc. | Collection device for single step assay of oral fluids |
US8062908B2 (en) | 1999-03-29 | 2011-11-22 | Orasure Technologies, Inc. | Device for collection and assay of oral fluids |
US6303081B1 (en) * | 1998-03-30 | 2001-10-16 | Orasure Technologies, Inc. | Device for collection and assay of oral fluids |
FR2780317B1 (en) * | 1998-06-30 | 2000-08-11 | Vedalab | DEVICE FOR DETERMINING AN ANALYTE IN A LIQUID SAMPLE |
US6328931B1 (en) * | 1999-01-11 | 2001-12-11 | International Food Protection, Inc. | Analyte collection and assaying assembly |
US6197254B1 (en) * | 1999-01-11 | 2001-03-06 | International Food Protection | Self-contained assaying apparatus |
WO2001018235A2 (en) * | 1999-09-09 | 2001-03-15 | Eichrom Technologies, Inc. | Lateral flow device with metal oxide indicator and assay method employing same |
GB9924222D0 (en) * | 1999-10-14 | 1999-12-15 | Imp College Innovations Ltd | Assay device |
GB2356253B (en) * | 1999-11-09 | 2003-11-05 | Bruker Daltonik Gmbh | Contamination-free transfer of biological specimens |
US6998273B1 (en) * | 2000-02-09 | 2006-02-14 | A-Fem Medical Corporation | Collection device for lateral flow chromatography |
US6372516B1 (en) * | 2000-09-07 | 2002-04-16 | Sun Biomedical Laboratories, Inc. | Lateral flow test device |
US6818452B2 (en) * | 2001-04-23 | 2004-11-16 | Branan Medical Corp. | Lateral flow contact test apparatus |
DE10126583C2 (en) * | 2001-05-31 | 2003-05-08 | Envitec Wismar Gmbh | Device for collecting liquid samples |
KR100455298B1 (en) * | 2001-06-15 | 2004-11-09 | 주)녹십자 | Immunochromatographic assay device having transparent plastic backing and method for producing the same |
US7270959B2 (en) * | 2001-07-25 | 2007-09-18 | Oakville Hong Kong Company Limited | Specimen collection container |
US7879293B2 (en) * | 2001-09-28 | 2011-02-01 | Orasure Technologies, Inc. | Sample collector and test device |
DE10153925B4 (en) * | 2001-11-02 | 2005-08-11 | Unlimited Pharmaceutical Deutschland Gmbh | Test device for the detection of pharmacologically active compounds from saliva |
US7587793B2 (en) * | 2001-12-14 | 2009-09-15 | Bode Technology Group, Inc. | Evidence collection holder and storage method |
US20030186446A1 (en) * | 2002-04-02 | 2003-10-02 | Jerry Pugh | Test strip containers and methods of using the same |
CA2480833C (en) | 2002-04-10 | 2011-09-13 | Response Biomedical Corporation | Sensitive immunochromatographic assay |
US7175992B2 (en) * | 2002-04-10 | 2007-02-13 | Response Biomedical Corporation | Sensitive immunochromatographic assay |
US7611670B2 (en) * | 2002-04-23 | 2009-11-03 | Home Access Health Corporation | Quantitative analysis of a biological sample of unknown quantity |
WO2004036172A2 (en) * | 2002-05-09 | 2004-04-29 | Dennis Farwell | Bioweapon-detecting fibrous-network products and methods for making same |
WO2004033101A1 (en) * | 2002-10-11 | 2004-04-22 | Zbx Corporation | Diagnostic devices |
TW580376B (en) * | 2002-10-24 | 2004-03-21 | Oncoprobe Biotech Inc | Test pen |
EP1565745A4 (en) * | 2002-11-12 | 2007-06-27 | Strategic Diagnostics Inc | Isolation and confirmation of analytes from test devices |
US7560272B2 (en) | 2003-01-04 | 2009-07-14 | Inverness Medical Switzerland Gmbh | Specimen collection and assay container |
US20040133128A1 (en) * | 2003-01-04 | 2004-07-08 | Zhumin Guan | Assay device with attachable seal for use with specimen collection and assay containers |
GB0300820D0 (en) * | 2003-01-14 | 2003-02-12 | Diagnoswiss Sa | Membrane-microchannel strip |
US7090803B1 (en) * | 2003-10-28 | 2006-08-15 | American Bio Medica Corporation | Lateral flow immunoassay device |
CN101876657B (en) | 2003-11-14 | 2013-08-28 | 美艾利尔瑞士公司 | Rapid sample detection and storage devices and methods of use |
US7244252B2 (en) * | 2003-11-25 | 2007-07-17 | Scimed Life Systems, Inc. | Medical device with visual indicator and related methods of use |
US6895889B1 (en) * | 2004-03-09 | 2005-05-24 | Richard J. Roush | Airborne hazard detector |
US7763454B2 (en) | 2004-07-09 | 2010-07-27 | Church & Dwight Co., Inc. | Electronic analyte assaying device |
US7442557B1 (en) | 2004-10-22 | 2008-10-28 | Idexx Laboratories, Inc. | Bi-directional flow assay device with reagent bridge |
WO2006098804A2 (en) | 2005-03-11 | 2006-09-21 | Chembio Diagnostic Systems, Inc. | Dual path immunoassay device |
US7189522B2 (en) | 2005-03-11 | 2007-03-13 | Chembio Diagnostic Systems, Inc. | Dual path immunoassay device |
US8166906B2 (en) * | 2005-04-29 | 2012-05-01 | Ambrozy Rel S | Stimulus indicating device employing polymer gels |
US20120032117A1 (en) | 2005-04-29 | 2012-02-09 | Ambrozy Rel S | Stimulus indicating device employing polymer gels |
US7940605B2 (en) * | 2005-04-29 | 2011-05-10 | Prasidiux, Llc | Stimulus indicating device employing polymer gels |
US8077554B2 (en) * | 2005-04-29 | 2011-12-13 | Ambrozy Rel S | Stimulus indicating device employing polymer gels |
US9182292B2 (en) | 2005-04-29 | 2015-11-10 | Prasidiux, Llc | Stimulus indicating device employing polymer gels |
WO2006119141A2 (en) * | 2005-04-29 | 2006-11-09 | Ambrozy Rel S | Stimulus indication employing polymer gels |
DE202005011777U1 (en) * | 2005-07-21 | 2006-11-30 | Engel, Matthias W. | Sample analyte concentration sensor for drug testing has housing with removable fluid impermeable barrier between detachable sample collector and chromatographic carrier |
DE212006000062U1 (en) * | 2005-10-25 | 2008-07-03 | Inverness Medical Switzerland Gmbh | Device for detecting an analyte in a sample |
WO2007062575A1 (en) | 2005-11-30 | 2007-06-07 | Inverness Medical Switzerland Gmbh | A device for detecting the presence or amount of an analyte in a fluid sample and method thereof |
US7618810B2 (en) * | 2005-12-14 | 2009-11-17 | Kimberly-Clark Worldwide, Inc. | Metering strip and method for lateral flow assay devices |
WO2007098184A2 (en) * | 2006-02-21 | 2007-08-30 | Nanogen, Inc. | Methods and compositions for analyte detection |
GB2435512A (en) | 2006-02-23 | 2007-08-29 | Mologic Ltd | A binding assay and assay device |
GB2435510A (en) * | 2006-02-23 | 2007-08-29 | Mologic Ltd | Enzyme detection product and methods |
GB2435511A (en) | 2006-02-23 | 2007-08-29 | Mologic Ltd | Protease detection |
US7473563B2 (en) * | 2006-04-03 | 2009-01-06 | The Clorox Company | Environmental sampling and testing device |
WO2008001737A1 (en) * | 2006-06-26 | 2008-01-03 | Nippon Telegraph And Telephone Corporation | Flow cell and process for manufacturing the same |
AU2007280929B2 (en) | 2006-07-26 | 2012-03-22 | Abbott Rapid Diagnostics International Unlimited Company | Analysis device for biological sample |
US7935538B2 (en) | 2006-12-15 | 2011-05-03 | Kimberly-Clark Worldwide, Inc. | Indicator immobilization on assay devices |
US8377379B2 (en) * | 2006-12-15 | 2013-02-19 | Kimberly-Clark Worldwide, Inc. | Lateral flow assay device |
WO2008106021A1 (en) | 2007-02-26 | 2008-09-04 | Response Biomedical Corporation | Comparative multiple analyte assay |
WO2008109658A2 (en) * | 2007-03-05 | 2008-09-12 | Prasidiux, Llc | Stimulus indicating device employing polymer gels |
WO2009027935A2 (en) * | 2007-08-31 | 2009-03-05 | Koninklijke Philips Electronics N. V. | Biochemical sensor cartridge |
US8470609B2 (en) * | 2007-09-11 | 2013-06-25 | Jian Feng Chen | Versatile drug testing device |
GB2453743A (en) * | 2007-10-16 | 2009-04-22 | Porvair Filtration Group Ltd | Testing apparatus and method with one-way action |
GB0811132D0 (en) | 2008-06-18 | 2008-07-23 | Secr Defence | Detection device |
US20100209957A1 (en) * | 2008-06-20 | 2010-08-19 | Genvault Corporation | Biosample storage devices and methods of use thereof |
US20100022916A1 (en) | 2008-07-24 | 2010-01-28 | Javanbakhsh Esfandiari | Method and Apparatus for Collecting and Preparing Biological Samples for Testing |
WO2010031007A2 (en) | 2008-09-12 | 2010-03-18 | Genvault Corporation | Matrices and media for storage and stabilization of biomolecules |
US20100278692A1 (en) * | 2009-04-29 | 2010-11-04 | Jainfeng Chen | Novel drug checking cup for in field drug testing |
US8012770B2 (en) | 2009-07-31 | 2011-09-06 | Invisible Sentinel, Inc. | Device for detection of antigens and uses thereof |
EP2486120B1 (en) | 2009-10-09 | 2014-04-02 | Invisible Sentinel, Inc. | Device for detection of antigens and uses thereof |
CN105044320B (en) | 2010-03-25 | 2017-02-22 | 艾博生物医药(杭州)有限公司 | Detection apparatus for testing to-be-analyzed substance in liquid sample |
US8956859B1 (en) | 2010-08-13 | 2015-02-17 | Aviex Technologies Llc | Compositions and methods for determining successful immunization by one or more vaccines |
EP3608021A3 (en) | 2011-01-27 | 2020-04-22 | Invisible Sentinel, Inc. | Analyte detection devices, multiplex and tabletop devices for detection of analytes, and uses thereof |
US8603835B2 (en) | 2011-02-10 | 2013-12-10 | Chembio Diagnostic Systems, Inc. | Reduced step dual path immunoassay device and method |
WO2013134503A2 (en) | 2012-03-09 | 2013-09-12 | Invisible Sentinel, Inc. | Methods And Compositions For Detecting Multiple Analytes With A Single Signal |
GB201303730D0 (en) * | 2013-03-01 | 2013-04-17 | Bloomsbury Innovations Ltd | Apparatus |
US9480462B2 (en) * | 2013-03-13 | 2016-11-01 | The Regents Of The University Of California | Micropatterned textile for fluid transport |
EP2996808B1 (en) * | 2013-05-14 | 2019-11-27 | FibroTx OÜ | Lateral flow assay device |
US10035146B2 (en) * | 2013-05-24 | 2018-07-31 | Premier Biotech, Inc. | Multi-stage oral-fluid testing device |
CA2912010A1 (en) | 2013-06-19 | 2014-12-24 | Brightwake Limited | Cell collecting device |
US9352313B2 (en) | 2013-12-31 | 2016-05-31 | Hangzhou Ditu Technology Co., Ltd. | Device for collecting and testing analyte in a liquid sample |
CN111077309B (en) | 2014-04-02 | 2023-11-17 | 生化诊断系统公司 | Immunoassay with capture conjugate |
US10436782B2 (en) * | 2014-10-24 | 2019-10-08 | Hai Zhu | Device for immunochromatographic assay |
US20160116466A1 (en) | 2014-10-27 | 2016-04-28 | Chembio Diagnostic Systems, Inc. | Rapid Screening Assay for Qualitative Detection of Multiple Febrile Illnesses |
US9377457B1 (en) | 2015-10-19 | 2016-06-28 | Naishu Wang | Progressive compression driven flow cartridge for analyte detecting strip and method |
US9702872B1 (en) * | 2016-04-15 | 2017-07-11 | Dnt Scientific Research, Llc | Rapid diagnostic test device by driven flow technology |
US9632083B1 (en) * | 2016-04-15 | 2017-04-25 | Dnt Scientific Research, Llc | Rapid diagnostic test device by driven flow technology |
US9535061B1 (en) | 2016-06-29 | 2017-01-03 | Dnt Scientific Research, Llc | Multi-functional rapid diagnostic test device |
US11340213B2 (en) | 2016-07-08 | 2022-05-24 | Healgen Scientific Limited | Apparatus for detecting analyte in a liquid sample and method thereof |
CN106248926A (en) * | 2016-09-21 | 2016-12-21 | 成都测迪森生物科技有限公司 | A kind of mycotoxin Test paper |
CN106248925A (en) * | 2016-09-21 | 2016-12-21 | 成都测迪森生物科技有限公司 | A kind of mycotoxin test bar |
WO2018129056A1 (en) | 2017-01-04 | 2018-07-12 | The Research Foundation For The State University Of New York | Biomarker detection device |
WO2018128749A1 (en) * | 2017-01-06 | 2018-07-12 | Dnt Scientific Research, Llc | Rapid diagnostic test device by driven flow technology |
US9784733B1 (en) | 2017-06-22 | 2017-10-10 | Dnt Scientific Research, Llc | Rapid diagnostic test device by driven flow technology |
US9823244B1 (en) | 2017-07-31 | 2017-11-21 | Dnt Scientific Research, Llc | Digital progressive compression driven flow cartridge for analyte detecting device and method |
US10451613B1 (en) | 2018-11-09 | 2019-10-22 | Dnt Scientific Research, Llc | Rapid diagnostic test device and sampling method using driven flow technology |
EP3865874B1 (en) | 2020-02-13 | 2022-10-05 | Zhejiang Orient Gene Biotech Co., LTD | Distinguishing smoking e-cigarettes from smoking cigarettes |
US20210325388A1 (en) | 2020-04-16 | 2021-10-21 | Hangzhou Biotest Biotech Co., Ltd. | Lateral flow detection device for detecting a coronavirus by immunoassay |
CN114814206A (en) | 2020-04-30 | 2022-07-29 | 杭州博拓生物科技股份有限公司 | Lateral flow detection device for detecting coronavirus antibody by immunoassay |
CA3168406A1 (en) | 2021-08-27 | 2023-02-27 | Zhejiang Orient Gene Biotech Co., Ltd. | Test device for presence of an analyte |
US20230128887A1 (en) | 2021-10-21 | 2023-04-27 | Zhejiang Orient Gene Biotech Co., LTD | Foldable test tube rack |
GB2612803B (en) * | 2021-11-11 | 2023-11-22 | Abingdon Health Ltd | Lateral flow test apparatus |
CN116448494A (en) | 2022-01-10 | 2023-07-18 | 浙江东方基因生物制品股份有限公司 | Apparatus for producing collector for collecting sample |
CA3182128A1 (en) | 2022-01-11 | 2023-07-11 | Hangzhou Xunling Biotech Co., Ltd. | Test device for nucleic acid |
CA3167468A1 (en) | 2022-03-15 | 2023-09-15 | Zhejiang Orient Gene Biotech Co., Ltd. | Device for detecting an analyte in a liquid sample |
AU2023201301A1 (en) | 2022-05-23 | 2023-12-07 | Zhejiang Orient Gene Biotech Co., LTD | Test device for analyte in a fluid sample |
CN117168866A (en) | 2022-05-27 | 2023-12-05 | 杭州博拓生物科技股份有限公司 | Sample collector |
CN117423095A (en) | 2022-07-18 | 2024-01-19 | 浙江东方基因生物制品股份有限公司 | Automatic identification method, device and equipment for detection result of immunoreagent card |
Family Cites Families (35)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US5622871A (en) * | 1987-04-27 | 1997-04-22 | Unilever Patent Holdings B.V. | Capillary immunoassay and device therefor comprising mobilizable particulate labelled reagents |
NL7208092A (en) * | 1972-06-14 | 1973-12-18 | ||
ZA733612B (en) * | 1972-10-11 | 1974-04-24 | Merck Patent Gmbh | Container for test strips |
SE388694B (en) * | 1975-01-27 | 1976-10-11 | Kabi Ab | WAY TO PROVIDE AN ANTIGEN EXV IN SAMPLES OF BODY WHEATS, USING POROST BERAR MATERIAL BONDED OR ADSORBING ANTIBODIES |
US4059407A (en) * | 1976-04-14 | 1977-11-22 | Becton, Dickinson And Company | Disposable chemical indicators |
US4046514A (en) * | 1976-11-24 | 1977-09-06 | Miles Laboratories, Inc. | Test device and method for determining a component in a sample |
US4200690A (en) * | 1976-12-16 | 1980-04-29 | Millipore Corporation | Immunoassay with membrane immobilized antibody |
US4703017C1 (en) * | 1984-02-14 | 2001-12-04 | Becton Dickinson Co | Solid phase assay with visual readout |
TW203120B (en) * | 1985-10-04 | 1993-04-01 | Abbott Lab | |
US5160701A (en) * | 1986-02-18 | 1992-11-03 | Abbott Laboratories | Solid-phase analytical device and method for using same |
US4916056A (en) * | 1986-02-18 | 1990-04-10 | Abbott Laboratories | Solid-phase analytical device and method for using same |
AU602694B2 (en) * | 1986-06-09 | 1990-10-25 | Ortho Diagnostic Systems Inc. | Improved colloidal gold membrane assay |
CA1303983C (en) * | 1987-03-27 | 1992-06-23 | Robert W. Rosenstein | Solid phase assay |
DE3856542T2 (en) * | 1987-04-27 | 2003-10-30 | Inverness Medical Switzerland | Test device for carrying out specific binding tests |
US4943522A (en) * | 1987-06-01 | 1990-07-24 | Quidel | Lateral flow, non-bibulous membrane assay protocols |
US4956302A (en) * | 1987-09-11 | 1990-09-11 | Abbott Laboratories | Lateral flow chromatographic binding assay device |
US4874691A (en) * | 1987-10-16 | 1989-10-17 | Quadra Logic Technologies Inc. | Membrane-supported immunoassays |
US5275785A (en) * | 1987-10-30 | 1994-01-04 | Unilever Patent Holdings B.V. | Test device for detecting an analyte in a liquid sample |
AU2684488A (en) * | 1988-06-27 | 1990-01-04 | Carter-Wallace, Inc. | Test device and method for colored particle immunoassay |
US5082626A (en) * | 1988-08-08 | 1992-01-21 | Boehringer Mannheim Gmbh | Wedge shaped test strip system useful in analyzing test samples, such as whole blood |
IT1227293B (en) * | 1988-10-06 | 1991-04-05 | Boehringer Biochemia Srl | DEVICE AND METHOD FOR PREGNANCY DIAGNOSIS |
GB8903627D0 (en) * | 1989-02-17 | 1989-04-05 | Unilever Plc | Assays |
US5416000A (en) * | 1989-03-16 | 1995-05-16 | Chemtrak, Inc. | Analyte immunoassay in self-contained apparatus |
US5252496A (en) * | 1989-12-18 | 1993-10-12 | Princeton Biomeditech Corporation | Carbon black immunochemical label |
US5648269A (en) * | 1991-05-03 | 1997-07-15 | Joseph R. Lakowicz | pH and pCO2 sensing by luminescent lifetimes and energy transfer |
US5726010A (en) * | 1991-07-31 | 1998-03-10 | Idexx Laboratories, Inc. | Reversible flow chromatographic binding assay |
DE69220871T2 (en) * | 1991-10-03 | 1997-11-20 | Bayer Ag | Device and method for the separation and analysis of whole blood |
DK88293A (en) * | 1992-08-03 | 1994-02-04 | Becton Dickinson Co | Solid Phase Analysis |
US5820826A (en) * | 1992-09-03 | 1998-10-13 | Boehringer Mannheim Company | Casing means for analytical test apparatus |
US5384264A (en) * | 1992-11-05 | 1995-01-24 | Syntron Bioresearch, Inc. | Method and apparatus for single step assays of ligand-containing fluids |
DK0653639T3 (en) * | 1993-11-12 | 2000-07-24 | Unilever Nv | Analytical devices and methods for their use |
US5660991A (en) * | 1994-10-28 | 1997-08-26 | Lakowicz; Joseph R. | Long lifetime anisotropy (polarization) probes for clinical chemistry, immunoassays, affinity assays and biomedical research |
US5739041A (en) * | 1995-05-02 | 1998-04-14 | Carter Wallace, Inc. | Diagnostic detection device |
AU731250B2 (en) * | 1995-11-13 | 2001-03-29 | Cortecs (Uk) Limited | Diagnostic test apparatus |
US5900379A (en) * | 1996-04-11 | 1999-05-04 | Mizuho Usa, Inc. | Analytical device |
-
1998
- 1998-09-18 US US09/156,770 patent/US6140136A/en not_active Expired - Fee Related
- 1998-12-29 WO PCT/US1998/027705 patent/WO2000017626A1/en active IP Right Grant
- 1998-12-29 AT AT98250453T patent/ATE208498T1/en not_active IP Right Cessation
- 1998-12-29 DE DE69802412T patent/DE69802412T2/en not_active Expired - Fee Related
- 1998-12-29 AU AU20180/99A patent/AU770689B2/en not_active Ceased
- 1998-12-29 TW TW087121794A patent/TW459126B/en not_active IP Right Cessation
- 1998-12-29 CA CA002344453A patent/CA2344453A1/en not_active Abandoned
- 1998-12-29 EP EP98250453A patent/EP1003037B1/en not_active Expired - Lifetime
-
1999
- 1999-09-17 GB GB9922064A patent/GB2342993A/en not_active Withdrawn
-
2001
- 2001-08-06 US US09/924,309 patent/US20030207466A1/en not_active Abandoned
Also Published As
Publication number | Publication date |
---|---|
GB9922064D0 (en) | 1999-11-17 |
AU770689B2 (en) | 2004-02-26 |
DE69802412D1 (en) | 2001-12-13 |
EP1003037A1 (en) | 2000-05-24 |
WO2000017626A1 (en) | 2000-03-30 |
DE69802412T2 (en) | 2002-06-27 |
GB2342993A (en) | 2000-04-26 |
TW459126B (en) | 2001-10-11 |
US20030207466A1 (en) | 2003-11-06 |
ATE208498T1 (en) | 2001-11-15 |
AU2018099A (en) | 2000-04-10 |
EP1003037B1 (en) | 2001-11-07 |
US6140136A (en) | 2000-10-31 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
EP1003037B1 (en) | Analytical test device and method of use | |
EP0987550B1 (en) | Analytical test device and method of use | |
US5384264A (en) | Method and apparatus for single step assays of ligand-containing fluids | |
AU2008221293B2 (en) | Diagnostic detection device | |
CA2493616C (en) | Rapid diagnostic device, assay and multifunctional buffer | |
JP3125788B2 (en) | Test apparatus and method for colored particle immunoassay | |
US20070087450A1 (en) | Immuno-gold lateral flow assay | |
WO1998036278A1 (en) | Multiple-site antibody capture immunoassays and kits | |
JP2000321278A (en) | Improved immunochromatographic analysis | |
WO2019124532A1 (en) | Immunochromatography device | |
JP2001228151A (en) | Immunological chromatographic device | |
EP0884594A2 (en) | Analyte-fixation immunochromatographic device |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
FZDE | Discontinued |